WO1999035156A1 - Novel macrolides - Google Patents

Novel macrolides Download PDF

Info

Publication number
WO1999035156A1
WO1999035156A1 PCT/IB1998/002099 IB9802099W WO9935156A1 WO 1999035156 A1 WO1999035156 A1 WO 1999035156A1 IB 9802099 W IB9802099 W IB 9802099W WO 9935156 A1 WO9935156 A1 WO 9935156A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
groups
substituted
optionally
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1998/002099
Other languages
French (fr)
Other versions
WO1999035156B1 (en
Inventor
John Philip Dirlam
Hamish Alastair Irvine Mcarthur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL13702498A priority Critical patent/IL137024A0/en
Priority to AU14447/99A priority patent/AU756409B2/en
Priority to BR9814601-7A priority patent/BR9814601A/en
Priority to HU0100420A priority patent/HUP0100420A3/en
Priority to US09/554,988 priority patent/US6472371B1/en
Priority to HR20000442A priority patent/HRP20000442A2/en
Priority to CA002316919A priority patent/CA2316919C/en
Priority to SK978-2000A priority patent/SK9782000A3/en
Priority to EP98958384A priority patent/EP1044207A1/en
Priority to KR1020007007313A priority patent/KR100352809B1/en
Priority to PL98341642A priority patent/PL341642A1/en
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to JP2000527552A priority patent/JP2002500230A/en
Priority to NZ504986A priority patent/NZ504986A/en
Priority to EA200000594A priority patent/EA200000594A1/en
Publication of WO1999035156A1 publication Critical patent/WO1999035156A1/en
Publication of WO1999035156B1 publication Critical patent/WO1999035156B1/en
Priority to IS5528A priority patent/IS5528A/en
Priority to NO20003347A priority patent/NO20003347L/en
Anticipated expiration legal-status Critical
Priority to BG104644A priority patent/BG104644A/en
Priority to US10/209,682 priority patent/US7015203B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Definitions

  • This invention relates to novel erythromycins and azalides that are useful as antibacterial agents and antiprotozoa agents and other applications (e.g , anticancer, atherosclerosis, gastric mo lity reduction, etc.) in mammals, including man, as well as in fish and birds.
  • This invention also relates to pharmaceutical compo ⁇ itions containing the novel compounds and to methods of treating bacterial infections and protozoa infections and in mammals, fish and birds by administering the novel compounds to mammals, fish and birds requiring such treatment
  • Macrolide antibiotics are known to be useful In the treatment of a broad sprectrum of bacterial infections and protozoa infections in mammals, fish and birds.
  • Such antibiotics include various derivatives of erythromycin A such as azithromycin which is commercially available and is referred to in United States patents 4,474,758 and 4,517,359, both of which are incorporated herein by reference in their entirety.
  • Additional macrolides are referred to in U.S. patent application serial number 60/063676, filed October 29, 1597 (Yong-Jin Wu), U.S appiication serial number 60/063161, filed October 29, 1997 (Yong-Jin Wu), U.S.
  • PCT/GB97/01810 filed July 4, 1997 (Peter Francis Leadlay, James Staunton, Jesus Cortes and Michael Stephen Pacey), International Application No. PCT/GB97/01819 filed July 4, 1997 (Peter Francis Leadlay, James Staunton, and Jecuc Cort ⁇ e), U.S. application serial no, 60/070343, filed January 2, 1998, (Diriam), U.S. application serial no, 60/070358, filed January 2, 1998 (Yong-Jin Wu) and U.S. application serial no. 60 ⁇ 097075, filed August 19, 1998 (He ⁇ grniao Cheng, Michael A. Letavic, Carl B. Ziegier, Jason K, Dutra, Bnan S.
  • novel macrolide compounds of the present invention possess potent activity against various bacterial infections and protozoa infections as described below. Summary of the Invention The present invention relates to compounds of the formula
  • Y is H, d-Cio alkyl, c 2 -C-
  • m is an inteoer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl groups are optionally substituted by 1 to 3 sub ⁇ tituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(0)R Z1 , -OC(0)R 21 , - NR 21 C(0)R 22 , -C(0)NR 21 R 22 , -NR 21 R 22 , hydroxy, C,-C 6 alkyl, C r C ⁇ alkoxy, C 6 -C 10 aryl, and 5- 10 membered heteroaryl;
  • R 1 is an alpha-branched Cj-C 8 alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a Cs-C ⁇ cycloalkylalkyl group wherein the alkyl group is an alpha-branched C C 5 alkyl group; a C,-C 3 cycloalkyl or C 5 -C profession cycloalke ⁇ yl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more C,-C alkyl groups or halo atoms: or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more 0,-0-, alkyl groups or halo atoms; or R 1 is phenyl which may be optionally substituted with at least one substitu
  • X is O, S or -CH 2 -, a, b, c, and d are each independently an integer ranging from 0 to 2 and a + b ⁇ c + d ⁇ 5; or R 1 is CH 2 R 2 *, wherein R 24 is H, C.-C a alkyl, C 2 -C 8 alkenyl, C 2 -C ⁇ alkynyl, alkoxyalkyl or alkylihloalkyl containing from 1 to s carbon aioms In each alkyl or alkoxy group wherein any of said alkyl. alkoxy.
  • alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a ( VC ⁇ cycloalkyl or C 3 -C B cycloalkenyl either or which may be optionally substituted by methyl or one or more C,-C 4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated or fully or partially unsaturated and which may optionally be substituted by one or more d-C ⁇ alkyl groups or halo atoms; or a group of the formula SR 43 wherein R 23 is C n - C 8 alkyl, C 2 -C Threadalkenyl, C 2 -C 8 a
  • R 2 is H or OH
  • R 9 is H, OH, or OCH 3 ;
  • R 4 is H, -C(0)R 9 , -C(0)OR 9 , -C(0)NR 8 R 10 or a hydroxy protecting group;
  • R 5 is -SR 8 , -(CH 2 ) n C(0)R ⁇ wherein n is 0 or 1 , C,-C 10 alkyl, C 2 -C 10 alkenyl, C 2 -
  • each R 6 and R 7 is independently H, hydroxy, C r C s alkoxy, C r C, alkyl, C 2 -C ⁇ alkenyl, C 2 -C 6 alkynyl, -(CH 2 ) m (C 6 -C 10 aryl), or -(CH 2 ) m (5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4;
  • each R B is independently H, C r C 10 alkyl, C2-C 10 alkenyl, C 2 -C 10 alkynyl, -(CH 2 ) e( CR 11 R 1z (CH 2 ) l
  • a 4-7 membered saturated ring is formed that optionally includes 1 or 2 carbon-carbon double or triple bonds; or R S and R 14 are taken together to form a 4-10 membered monocyclic or poiycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein 3aid saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S and -N(R B )-, in addition to the nitrogen to which R 13 and R 14 are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R 1s groups;
  • R 1S is H. C ⁇ -C, 6 alkyl, C a -C 10 alkenyl. Or C z -C,_ alkynyl, wherein the foregoing R 1S groups are optionally substituted by 1 to 3 substituents independently selected from halo and - OR 9 ; each R 1B is independently selected from halo, cyano, nitro, trifluoromethyl, azido, - C(0)R 17 , -C(0)OR 17 , -C(0)OR 17 , -OC(0)OR 17 , -NR 6 C(0)R 7 , -C(0)NR 8 R 7 , -NR 6 R 7 , hydroxy, C-rCg alkyl, C
  • each R 17 is independently selected from H, C C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, -(CH 2 ) m (C e -C 10 aryl), and -(CH 2 ) m (5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, provided that R a is not H where R 1 ⁇ is -CH 2 S(0) n R e ; R 1, is OH;
  • R 9 is C r C,o alkyl, C 2 -C 10 alkenyl, C 2 -C, 0 alkynyl, cyano, -CHjS(O) 0 R 8 wherein n is an integer ranging from 0 to 2, -CH 2 OR e , -CH 2 N(OR 9 )R e , -CH 2 NR*R 15 , -(CH 2 ) m (C e -C, Q aryl), or - (CH 2 ) m (5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R 10 groups are optionally substituted by i to 3 R 1 ⁇ groups; or R 1 ⁇ and R 19 are taken together to form an oxazolyl ring as shown below
  • each R 21 and R 22 is independently H, hydroxy, C r C ⁇ alkoxy, C,-C ⁇ alkyl, C 2 -C ⁇ alkenyl, (CH z ) m (C 6 -C 1D ) aryl, (CH 2 ) m (5-1 ⁇ membered heteroaryl), wherein m Is an integer ranging from 0 to 4, or C 2 -C
  • the present invention further relates to compounds of the formula
  • Y is H, C t -C 10 alkyl, C 2 -C 10 alkenyl, C z -C l0 alkynyl, -(CH 2 ) m C 6 -C l0 aryl, -(CH 2 ) m (5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(0)R 2 ⁇ -OC(0)R 21 , - NR 21 C(0)R 22 , -CfOJN ⁇ R 22 , -NR 2l R a hydroxy, C,-C 6 alkyl, C,-C 6 alkoxy, C B -C, 0 aryl, and 5- 10 membered heteroaryl; R 1 Is an
  • X is O, S or -CH 2 -, a, b, c, and d are each independently 0-2 and a + b + c + d ⁇ 5; or R 1 is CH t R 24 , wherein R 24 is H, C,-C B alkyl, d-C ⁇ alkenyl, C C B alkynyl, alkoxyalkyl or alkylthioalkyl containing from 1 to 6 carbon atoms in each alkyl or alkoxy group wherein any of said alkyl, alkoxy, alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a C 3 -C ⁇ cycloalkyl or C 5 -C B cycloalkenyl either or which may be optionally substituted by methyl or one or more C r C 4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or
  • R z is H or OH;
  • R 3 is H, OH, or OCH 3 ;
  • R 4 is H, -C(0)R 9 , -C(0)OR B , -C(0)NR 9 R 10 or a hydroxy protecting group;
  • each R 9 and R 19 is independently H or d-d alkyl;
  • R" is OH;
  • each R 21 and R 22 is independently H, hydroxy, C r C Pain alkoxy, C r C s alkyl, C 2 -C 6 alkenyl, (CH 2 ) m (C 8 -C,o) aryl, (CH 2 ) m (5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, or C 2 -C l0 al ytyl.
  • the compounds of formula I are exemplified by the compounds of formulas 5 and 6, described below, wherein Y m H and CH 3 , respectively.
  • R 1 is isopropyl, R 2 is H and R 1 ⁇ is OH;
  • R 1 is isopropyl, R 2 is OH and R 19 is OH;
  • R 1 is cyclopropyl, R 2 is H and R 19 is OH;
  • R 1 is cyclopropyl, R z is OH and R 1 ⁇ is OH;
  • R 1 is sec-butyl, R 2 is H and R 1 ⁇ is OH;
  • R 1 is sec-butyl, R 2 is OH and R 19 is OH;
  • R 1 Is cyclobutyl, R 2 Is H and R 19 Is OH;
  • R 1 is cyclobutyl, R 2 is OH and R 19 is OH;
  • R 1 is cyclopentyl, R 2 is H and R 19 is OH;
  • R 1 is cyclopentyl, R 2 is OH and R 1 ⁇ is OH; R 1 is methylthioethyl, R z is H and R 19 is OH;
  • R 1 is methylthioethyl, R 2 is OH and R 1 ⁇ is OH;
  • R 1 is 3-furyl
  • R 2 is H
  • R 19 is OH and or
  • R 1 is 3-furyl
  • R 2 is OH
  • R 19 is OH
  • the invention further relates to compounds of the 2, 2a, 3, 3a, 4, 5, 6, 7, 8, 9, 10, 11. 12. H. H. J!, .16. 17 and 18.
  • the invention further relates to a compound of the formula
  • R 1 is an alpha-branched d-d alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C 5 -C 3 cycloalkylalkyl group wherein the alkyl group is an alpha-branched C 2 -C 3 alkyl group; a C 3 -C 3 cycloalkyl or C 5 -C.
  • R 1 is phenyl which may be optionally substituted with at least one substituent selected from C r C 4 alkyl, C,-C 4 alkoxy and C,-C 4 alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano; or R may be with a formula (a) as shown below:
  • R 1 is CH 2 R 24 , wherein R* 4 is H, C,-C B alkyl, C 2 -C B alkenyl, C 2 -C 8 alkynyl, alkoxyalkyl or alkylthioalkyl containing from 1 to 6 carbon atoms in each alkyl or alkoxy group wherein any of said alkyl, alkoxy, alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a C 3 -C 8 cycloalkyl or C r C 8 cycloalkenyl either or which may be optionally substituted by methyl or one or more C,-C 4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or s
  • R 2 is H or OH.
  • the invention further relates to a compound of the formula
  • R 1 is an alpha-branched C 3 -C B alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C 3 -C 8 cycloalkylalkyl group wherein the alkyl group is an alpha-branched C 2 -C 3 alkyl group; a C 3 -C 8 cycloalkyl or d-C, cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more d-d alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C,-d alkyl groups or halo atoms; or R' is phenyl, alkynyl, alk
  • X is O, S or -CH Z -, a, b, o, and d are each independently 0-2 and a + b + c * d ⁇ 6; or R 1 is CHj-R 24 , wherein R 24 is H, C,-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C B alkynyl, alkoxyalkyl or alkylthioalkyl containing from 1 to 6 carbon atoms in each alkyl or alkoxy group wherein any of said alkyl, alkoxy, alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a Ca-C ⁇ cycloalkyl or C 3 -C 8 cycloalkenyl either or which may be optionally substituted by methyl or one or more C,-C 4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or s
  • the invention also relates to a pharmaceutical composition for the treatment of a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises a therapeutlcally effective amount of a compound of formulas I, II, 8, or 9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the invention also relates to a method of treating a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises administering to said mammal, fish or bird a therapeutically effective amount of a compound of formula I, II, 8, or 9, or a pharmaceutically acceptable salt thereof.
  • the invention also relates to a process for preparing a compound of the formula
  • R 1 and R 2 are as defined for the compound of formula I, which comprises treating a compound of the formula
  • R 1 and R 2 are as defined for the compound of formula I, with a reducing agent
  • the invention also relates to the above process wherein the reducing agent is NaBH 4 or platinum oxide.
  • the invention also relates to a process for preparing a compound of the formula
  • R 1 and R 2 are as defined for the compound of formula I, which comprises treating a compound of the formula
  • R* and R 2 are as defined for the compound of formula I, with a methylating agent.
  • Trie Invention also relates to the above process wherein the methylating agent Is formaldehyde.
  • the invention also relates to a process for preparing a compound of the formula
  • R 1 and R 2 are as defined for the compound of formula I, which comprises treating a compound of the formula
  • R 1 and R 2 are as defined for the compound of formula I, with a reducing agent.
  • the invention also relates to the above process wherein the reducing agent is NaBH 4 or platinum oxide.
  • the invention also relates to a process for preparing a compound of the formula
  • R 1 and R 2 are as defined for the compound of formula I, which comprises treating a compound of the formula
  • R 1 and R 2 are as defined for the compound of formula I, with a methylating agent.
  • the Invention also relates to tha above process wherein the methylating agent is formaldehyde.
  • the invention also relates to a compound of the formula
  • Y is H, d-C . o alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, -(CH 2 ) m C 6 -C 10 aryl, -(CH 2 ) m (5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(0)R 21 , -OC(0)R 21 , - NR 21 C(0)R 22 , -C(0)NR 21 R 2Z , -NR 1 R 22 , hydroxy, d-C 3 alkyl, d- alkoxy, C 6 -C 1Q aryl, and 5- 10 membered heteroaryl;
  • R 1 is an alpha-branched C 3 -C Conduct alkyl. alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C S -C B cycloalkylalkyl group wherein the alkyl group is an alpha-branched d-d alkyl group; a d-d cycloalkyl or C 3 -C 8 cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more C r C 4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C alkyl groups or halo atoms; or R 1 is phenyl which may be optionally substituted with at least one substituent selected
  • R 2 is H or OH
  • R 3 is H, OH, or OCH 3 ;
  • R 4 is H, -C(0)R 9 , -C(0)OR*, -C(0)NR* R 1 ⁇ or a hydroxy protecting group
  • R 6 is -SR 8 , -(CH 2 ) friendshipC(0)R 8 wherein n is 0 or 1, C,-C 10 alkyl, C 2 -C 10 alkenyl, C 2 - do alkynyl, -(CH 2 ) m (C ⁇ -C,o aryl), or -(CH 2 ) m (5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R s groups are optionally substituted by 1 to 3 R 18 groups; each R a ⁇ d R 7 is independently H, hydroxy, 0,-0 8 alkoxy, 0-,-C ⁇ alkyl, C 2 -C 6 alkenyl, C 2 -C classroom alkynyl, -(CH 2 ) r ⁇ (C 6 -C 10 aryl
  • R 1S is H, d-C 1p alkyl, C 2 -C 10 alkenyl, or C 2 -C 10 alkynyl, wherein the foregoing R lS groups are optionally substituted by 1 to 3 substituents independently selected from halo and - OR ⁇ ; each R 1S is independently selected from halo, cyano, nitro, trifluoromethyl, azido, - C(0)R 17 , -C(0)OR 17 , -C(0)OR 17 , -OC(0)OR 17 , -NR 6 C(0)R 7 , -C(0)NR 6 R 7 , -NR 6 R 7 , hydroxy, C,-C 6 alkyl, CrC 6 alkoxy, -(CH 2 ) m (C 6 -C 10 aryl), and -(CH 2 ) m (5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein said aryl and heteroaryl subsituent
  • each R 17 is independently selected from H, C C 0 alkyl, C j -C 1D alkenyl, Ci-C 1 ⁇ alkynyl, -(CH 2 ) m (d-do aryl), and -(CH 2 ) m (5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, provided that R ⁇ is not H where R 19 is -CH 2 S(0) n R B ; R 1B is OH;
  • R 19 is d-C 10 alkyl, C r C 10 alkenyl, C 2 -C 1Q alkynyl, cyano, -CH 2 S(0) n R B wherein ⁇ is an integer ranging from 0 to 2, -CH 2 0R 8 , -CH 2 N(OR ⁇ )R ⁇ , -CH 2 NR B R 15 , -(CH a ) -do aryl), or - (CH 2 ) m (5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R 1B groups are optionally substituted by 1 to 3 R 16 groups; or R 1a and R 19 are taken together to form an oxazolyl ring as shown below
  • each R 21 and R 22 is independently H, hydroxy, d-C B alkoxy, C,-C 6 alkyl, C 2 -C 6 alkenyl, (CH 2 ) m (C 6 -C 0 ) aryl, (CH 2 ) m (5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, or C 2 -C 10 alkylyl.
  • treatment includes the treatment or prevention of a bacterial infection or protozoa infection as provided in the method of the present invention.
  • bacterial infection(s) or "protozoa infections; includes bacterial infections and protozoa infections that occur in mammals, fish and birds as well as disorders related to bacterial infections and protozoa infections that may be treated or prevented by administering antibiotics such as the compounds of the present invention.
  • Such bacterial infections and protozoa infections and disorders related to such infections include the following; pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxalla catarrhalis, Staphylococcus aureus, or P ⁇ ptostreptococcus spp.; pharynigitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Clostridium diptheria ⁇ , or Actinobacillus ha ⁇ molytlcum; respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chlamydia pneumoniae; uncomplicated skin and soft tissue infections, abscesses and osteomyelitis, and puerper
  • aureus food poisoning and Toxic shock syndrome
  • Groups A, B, and C streptococci ulcers related to infection by H ⁇ llcobact ⁇ r pylori: systemic febrile syndromes related to WO 99/35156 _ ⁇ g _ PCT/IB98/02099
  • influenzae or List ⁇ ria spp.
  • disseminated Mycobact ⁇ rium avium complex (MAC) disease related to infection by Mycobacterium avium, or Mycobacterium intracellulare
  • gastroenteritis related to infection by Cdmpyl b ⁇ ct ⁇ r j ⁇ j ⁇ ni
  • intestinal protozoa related to infection by Cryptospo ⁇ dium spp.
  • odontogenic infection related to infection by viridans streptococci
  • persistent cough related to infection by Bordetella pertussis
  • gas gangrene related to infection by Clostridium perf ⁇ ngens or Bacteroides spp.
  • atherosclerosis related to infection by Helicobacter pylon or Chlamydia pneumoniae.
  • Bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in animals include the following: bovine respiratory disease related to infection by P. ha ⁇ m., P. multocida, Mycoplasma bows, or Bordetella spp.; cow enteric disease related to infection by E. coll or protozoa (i.e., coccidia, cryptosporidia, etc.); dairy cow mastitis related to infection by Sfap ⁇ .
  • aureus swine respiratory disease related to infection by A. pleuro., P. multocida, or Mycoplasma spp.
  • swine enteric disease related to infection by E. coli, Lawsonia intracellularis, Salmonella, or Serpulina hyodyisinteriae
  • cow footrot related to infection by Fusobacterium spp.
  • cow hairy warts related to infection by Fusobacterium necrophorum or Bacteroides nodosus cow pink-eye related to infection by Moraxalla bo ⁇ is; cow premature abortion related to infection by protozoa (i.e. neosporium); urinary tract infection in dogs and cats related to infection by £ coli; skin and soft tissue infections in dogs and cats related to infection by Staph. epidermidis, Staph. int ⁇ rmedius, coagulas ⁇ n ⁇ g. Staph. or P.
  • the present invention also relates to a method of preparing the above compounds of formulas I, II, 8, or 9.
  • the compounds used in the preparation of the compounds of formulas I, II, 8, and 9 can prepared using the methods described in International Application No. PCT/GB97/01810 filed July 4, 1997 (Peter Francis Leadlay, James Staunton, Jesus Cortes and Michael Stephen Pacey), and International Application No. PCT/GB97/01819 tiled July 4, 1997 (Peter Francis Leadlay, James Staunton, and Jesus Cortes), both of which are is incorporated herein by reference in their entirety.
  • the present Invention also relates to the compounds of formulas 2, 2a, 3 ⁇ 3a, and 4 to
  • hydroxy protecting group includes acetyl, benzyloxycarbonyl, and various hydroxy protecting groups familiar to those skilled in the art include the groups referred to in T. W. Greene, P. Q. M. Wuts, "Protective Groups In Organic Synthesis,” (J. Wiley & Sons, 1991),
  • halo as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo.
  • alkyr as used herein, unless otherwise Indicated, includes saturated monovalent hydrocarbon radicals having straight, cyclic or branched moieties, or mixtures thereof. It is to be understood that where cyclic moieties are intended, at least three carbons in said alkyl must be present Such cyclic moieties include cyclopropyl, cyclobutyl and cyclopentyl.
  • alkoxy as used herein, unless otherwise indicated, includes -O-alkyl groups wherein alkyl is as defined above.
  • aryl as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.
  • 5-10 membered heteroaryl includes aromatic heterocyclic groups containing one or more heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 5 to 10 atoms in its ring system.
  • Suitable 5-10 membered heteroaryl groups include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, (1 ,2,3,)- and (1 ,2,4)-triazolyl, pyra-zinyl, tatrazolyl, furyl, thionyl, isoxazolyl, oxazolyl, pyrrolyl and thiazolyl,
  • pharmaceutically acceptable salt(s) includes salts of acidic or basic groups which may be present in the compounds of the present invention.
  • the compounds of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
  • acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of the present invention are those that form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable anlons, such as the hydrochlorlde, hydrobromlde, hydrolodlde, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pa ⁇ tothenate, bitartrate, ascorbate, succi ⁇ ate, maleate, gentisinate, fumarate, gluconate, glucaronat ⁇ , saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfo ⁇ ate, p-toluenesulfonate and pamoate [i.e., l ,l'-methylene-bis-(2- hydroxy
  • Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
  • Examples of such salts include the alkali metal or alkaline earth metal salts and, particulariy, the calcium, magnesium, sodium and potassium salts of the compounds of the present invention.
  • Certain compounds of the present invention may have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms.
  • This invention relates to the use of all optical Isomers and stereolsomers of the compounds of the present invention, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment that may employ or contain them.
  • the present invention includes the compounds of the present invention, and the pharmaceutically acceptable salts thereof, wherein one or more hydrogen, carbon or other atoms are replaced by isotopes thereof.
  • Such compounds may be U3eful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays.
  • the compounds of the present invention are readily prepared.
  • the compounds used in the preparation of the compounds of formulas I, II, 8, and 9 can prepared using the methods described in International Appiication No. PCT/GB97/01810 filed July 4, 1997 (Peter Francis Leadlay, James Staunton, Jesus Cortes and Michael Stephen Pacey), and International Application No. PCT/GB97/01819 filed July 4, 1997 (Peter Francis Leadlay, James Staunton, and Jesus Cortes), both of which are Is Incorporated herein by reference in their entirety.
  • novel polyketides and methods and means for preparing them, and specifically the novel macrolides that are useful in the preparation of the compounds of the present invention are prepared by fermenting suitable organisms in the presence of where R 1 is as defined in claim 1 or claim 2.
  • a preferred organism is Saccharopolyspora erythraea preferably containing an integrated plasmid capable of directing synthesis of desired compounds,
  • polyketide biosynthetic genes or portions of them, which may be derived from different polyketide biosynthetic gene clusters are manipulated to allow the production of novel erythromycins,
  • Polyketides are a large and structurally diverse class of natural products that includes many compounds possessing antibiotic or other pharmacological properties, such as erythromycj ⁇ , tetracyclines, rapamycin, avermectin, polyether ionophores, and FK5D6.
  • antibiotic or other pharmacological properties such as erythromycj ⁇ , tetracyclines, rapamycin, avermectin, polyether ionophores, and FK5D6.
  • polyketides are abundantly produced by Streptomyces and related actinomycete bacteria.
  • PKS polyketide synthase
  • Naturally module refers to the set of contiguous domains, from a ⁇ -ketoacylsynthase (“KS”) gene to the next acyl carrier protein (“ACP”) gene, which accomplishes one cycle of polyketide chain extension.
  • KS ⁇ -ketoacylsynthase
  • ACP acyl carrier protein
  • combinatorial module is used to refer to any group of contiguous domains (and domain parts), extending from a first point in a first natural module, to a second equivalent point in a second natural module.
  • the first and second points will generally be in core domains which are present in all modules, i.e., both at equivalent points of respective KS, AT (acyl transferase), ACP domains, or in linker regions between domains.
  • T e organisation of the erythromycin producing PKS, (also known as ⁇ - deoxyerythronolide B synthase, DEBS) genes contains three open reading frames encode the DEBS polypeptides. The genes are organised in six repeated units designated modules.
  • the first open reading frame encodes the first multi-enzyme or cassette (DEBS1) which consists of three modules: the loading module (ery_-load) and two extension modules (modules 1 and 2).
  • the loading module comprises an acyl transferase and an acyl carrier protein.
  • the complex polyketides produced by modular Type I PKS's are particularly valuable, in that they include compounds with known utility as anthelminthics, insecticides, immunosuppressants, antifungal, and/or antibacterial agents. Because of their structural complexity, such novel polyketides are not readily obtainable by total chemical synthesis, or by chemical modifications of known polyketides.
  • the Type I PKS gene assembly encodes a loading module which is followed by extension modules. It is particularly useful to provide a hybrid PKS gene assembly in which the loading module is heterologous to the extension modules and is such as to lead to a polyketide having an altered starter unit.
  • W093/13863 refers to altering PKS genes by inactivating a single function (i.e. a single enzyme) or affecting "an entire module" by deletion, insertion, or replacement thereof.
  • the loading assembly in their terms, is not a module.
  • the hybrid gene assembly can be used to produce many different polyketide ⁇ .
  • a hybrid gene assembly may employ nucleic acid encoding an avr loading module with ery extender modules.
  • a loading module may accept unnatural acid units and derivatives thereof, the avr loading module is particulariy useful in this regard (Dutto ⁇ et al,, (1991) J. Antibiot., 44:357-365).
  • Methyl and other substituents can be added or removed by acyltransferase domain replacement or total module replacement. Consequently, it also becomes apparent to those skilled in the art that it is possible to combine the use of the relaxed substrate specificity of the erythromycin loading module with extension module replacement and hybrid leading module substitution with extension module replacement as a mechanism to produce a wide range of novel erythromycins.
  • International Application PCT/GB97/01810 describes the production of novel erythromycins by non-transformed organisms and also such gene assemblies, vectors containing such gene assemblies, and transformant organisms that can express them to produce novel erythromycins in transformed organisms. Transformant organisms may harbour recombinant plasmids, or the plasmids may integrate.
  • a plasmid with an int sequence will integrate into a specific attachment site (att) of a host's chromosome.
  • Transformant organisms may be capable of modifying the initial products, e.g., by carrying out all or some of the biosynthetic modifications normal in the production of erythromycins. However, use may be made of mutant organisms such that some of the normal pathways are blocked, e.g., to produce products without one or more "natural" hydroxy-groups or sugar groups, for instance as described in WO 91/16334 or in Weber et al. (1985) J. Bacterlol. 164:425-433 hich are Incorporated herein by reference in their entirety.
  • the DNA is highly conserved here between all modular PKS's, and this may aid in the construction of hybrids that can be transcribed. It may also assist in maintaining the spacing of the active sites of the encoded enzymes, which may be important
  • the ery module together with a small amount of the following ketosynthase (KS) domain was removed.
  • the start of the KS domain (well spaced from the active site) is highly conserved and therefore provides a suitable splicing site as an alternative to the linker region between the loading domain and the start of the KS domain.
  • the excised er ⁇ module was then replaced by an avr loading module.
  • acyl transferase AT
  • ACP acyl carrier protein
  • KS acyl carrier protein
  • the excised loading module would have provided a propionate starter, and the replacement is intended to provide one or more different starters.
  • Propionate may feed into the KS of the extension module from a propionate pool in the host cell, leading to dilution of the desired products. This can be largely prevented by substituting an extended loading module including all or most of the KS domain.
  • the splice site may be in the end region of the KS gene, or early in the following AT gene, or the linker region between them.
  • a “combinatorial module” to be excised and/or replaced and/or inserted may extend from the corresponding domain of two natural-type modules, e.g., from the AT of one module to the AT of the next, or from KS to KS.
  • the splice sites will be in corresponding conserved marginal regions or in linker regions.
  • a combinatorial module can also be a 'double' or larger multiple, for adding 2 or more modules at a time.
  • An erythromycin analogue (being a macrolide compound with a 14-membered ring) in which a substituent R, on the C-13 position, bears a side-chain other than ethyl, generally a straight chain C3-C6 alkyl group, a branched C 3 -C 8 alkyl group, a C3-C 8 cycloalkyi or cycloalkenyl group (optionally substituted, e.g., with one or more hydroxy, C-)_ alkyl or alkoxy groups or halogen atoms), or a 3-6 membered heterocycle containing O or S, saturated or fully or partially unsaturated, optionally substituted (as for cycloalkyi), or R is phenyl which may be optionally substituted with at least one substituent selected from C,-C 4 alkyl, C 1 -C alkoxy and C,-C 4 alkylthio groups, halogen atoms, trifluoromethyl
  • Preferred candidate ⁇ for the C-13 substituent R are the groups of carboxylate units RCOOR', usable as substrates by an avr starter module, or rapamycin starter variants.
  • Preferred substrates are the carboxylic acids RCOOH.
  • Alternative substrates that can be effectively used are carboxylic acid salts, carboxylic acid esters, or amides.
  • Preferred esters are N- acetyl-cysteami ⁇ e thioesters which can readily be utilised as substrates by the avr starter module as illustrated by Dutton et al.
  • amides are N-acyl imidazoles.
  • Other alternative substrates that may be used are derivatives which are oxidative precursors for the carboxylic acids; thus, for example suitable substrates would be amino acids of the formula RCH(NH 2 )COOH, glyoxylic acids of the formula RCOCOOH, methylamine derivatives of the formula RCH a NH a , methanol derivatives of the formula RCH 2 OH, aldehydes of the formula RCHO or substituted alkanoie acids of the formula R(CH 2 ) n COOH wherein n is 2, 4, or 6.
  • examples of preferred substrates include isobutyrate (Risi-Pr) and 2-methylbutyrate (Ris1-methylpropyl).
  • Other possibilities include n-butyrate, cyclopropyl carboxylate, cyclobutyl carboxylate, cyclopentyl carboxylate cyclohexyl carboxylate, cycloheptanyl carboxylate, cyclohexenyl carboxylates, cycloheptenyl carboxylates, and ring-methylated variants of the cyclic carboxylates and the aforementioned derivatives thereof,
  • the erythromycin analogue may correspond to the initial product of a PKS (6- daoxyerythranolide) or the product after one or more of the normal biosynthetic steps. These comprise: 6-hydroxylation; 3-0-glycosylation; 5-0-glycosylation; 12-hydro ⁇ ylation; and specific sugar ethylation.
  • the analogues may include those corresponding to 6-deoxyerythronoiide B, erythromycin A, and various intermediates and alternatives thereof.
  • Erythromycin analogues differing from the corresponding 'natural' in the oxidation state of one or more of the ketjde units (i.e. selection of alternatives from the group: -CO-, - CH(OH)-. IsCH-. and -CH -).
  • PKS enzymes e.g., one or more of hydroxylation, epoxidation, glycosylation, and methylation.
  • unnatural starter units preferably, but not restricted to the carboxylic acid analogues or the unnatural starter units
  • a preferred approach involves introduction of the starter unit into fermentation broths of the erythromycin-producing organism, an approach which is more effective for transformed organisms capable of producing erythromycins.
  • the starter unit analogue can also be introduced to alternative preparations of the erythromycin- producing organisms, for example, fractionated or unfractionated broken-cell preparations. Again, this approach is equally effective for transformed organisms capable of producing erythromycins.
  • one or more segments of DNA encoding individual modules or domains within a heterologous Type I PKS have been used to replace the DNA encoding, respectively, individual modules or domains within the DEBS genes of an erythromycin-producing organism.
  • Loading modules and extension modules drawn from any natural or non-natural Type I PKS are suitable for this "donor” PKS but particularly suitable for this purpose are the components of Type I PKS's for the biosynthesis of erythromycin, rapamycin, avermectin, tetronasin, oleandomycin, monensin, amphotericin, and rifamycin, for which the gene and modular organisation is known through gene sequence analysis, at least in part.
  • the loading modules of the donor PKS are those loading modules showing a relaxed specificity, for example, the loading module of the avermectin (avr)-producing PKS of Streptomyces avermitilis; or those loading modules possessing an unusual specificity, for example, the loading modules of the rapamycin-, FK5D6- and ascomycin-producing PKS's. all of which naturally accept a shikimate-derived starter unit.
  • both the untransformed and genetically engineered erythromycin-producing organisms when cultured under suitable conditions have been found to produce non-natural erythromycins, and where appropriate, the products are found to undergo the same processing as the natural erythromycin.
  • the novel erythromycin products contain a starter unit typical of those used by the avr PKS.
  • Saccharopolyspora erythraea strains containing such hybrid PKS are found to produce 14-membered macrolides containing starter units typically used by the avr PKS,
  • erythromycin PKS placed under the control of a Type II PKS promoter and activator gene.
  • desired genes present on an SCP2*-derived plasmid are placed under the control of the bidirectional actl promoter derived from the actinorhodin biosynthetic gene cluster of Streptomyces coelicolor, and in which the vector also contains the structural gene encoding the specific activator protein Act ll-orf 4.
  • the recombinant plasmid is introduced into Saccharopolyspora erythraea, under conditions where either the introduced PKS genes, or PKS genes already present in the host strain, are expressed under the control of the actl promoter.
  • Such strains produce the desired erythromycin product and the activator gene requires only the presence of the specific promoter in order to enhance transcriptional efficiency from the promoter. This is particularly surprising in that activators of the Actll-orf4 family do not belong to a recognised class of DNA-binding proteins. Therefore it would be expected that additional proteins or other control elements would be required for activation to occur in a heterologous host not known to produce actinorhodin or a related isochromanequinone pigment.
  • the recombinant strains can produce more than ten-fold erythromycin product than when the same PKS genes are under the control of the natural promoter, and the specific erythromycin product is also produced precociously in growing culture, rather than only during the transition from growth to stationary phase, Such erythromycins are useful as antibiotics and for many other purposes in human and veterinary medicine.
  • the activator and promoter are derived from the actinorhodin PKS gene cluster and the actl/actll-orf4-regulated ery PKS gene cluster is housed in the chromosome, following the site-specific integration of a low copy number plasmid vector, culturing of these cells under suitable conditions can produce more than ten-fold total 14-membered macrolide product than in a comparable strain not under such heterologous control.
  • the activator and promoter are derived from the actinorhodin PKS gene cluster and the actl/actll-orf4-regulated ery PKS gene cluster is housed in the chromosome, following the site-specific integration of a low copy number plasmid vector, culturing of these cells under suitable conditions can produce more than ten-fold total 14-membered macrolide product than in a comparable strain not under such heterologous control.
  • the PKS genes under this heterologous control are hybrid Type I PKS genes whose construction is described herein, more than ten-fold hybrid polyketide product can be obtained compared to the same hybrid Type I PKS genes not under ⁇ uch control.
  • the hybrid Type I PKS genes are the ery PKS genes in which the loader module is replaced by the avr loading module, a ten-fold increase is found in the total amounts of novel 14-membered macrolides produced by the genetically engineered cells when cultured under suitable conditions as described in PCT/GB97/01810.
  • Erythromycin analogus described in International Application PCT/GB97/01810 are produced by fermentation of an untransformed or transformed organism capable of producing erythromycins, including but not limited to Saccharopolyspora species, Streptomyces griseoplanus, Nocardia sp., Micromonospora sp., Arthobacter sp., and Streptomyces antibioticus, but excluding S. coelicolor.
  • Particularly suitable in this regard are untransformed and transformed strains of Saccharopolyspora erythraea, for example NR L 2338, 18643, 21484.
  • Particularly preferred transformed strains are those in which the erythromycin loading module has been replaced with the loading module from the avermectin producer, Strepbmyces avermitilis, or the rapamycin producer, Streptomyces hygroscopicus.
  • the preferred method of producing compounds of the current invention is by fermentation of the appropriate organism in the presence of the appropriate carboxylic acid of the formula R.,COOH, wherein R, is as defined in formulae 1_ or 2 of International Application PCT/GB97/01810 or is R 1 of the compounds of the present invention, or a salt, ester (particularly preferable being the N-acetylcysteamine thioester), or amide thereof or oxidative precursor thereof.
  • the acid or derivative thereof is added to the fermentation either at the time of inoculation or at intervals during the fermentation.
  • Production of the compounds of this invention may be monitored by removing samples from the fermentation, extracting with an organic solvent and following the appearance of the compounds of this invention by chromatography, for example using high pressure liquid chromatography. incubation Is continued untB the yield of the compound of formulae 1_ or 2 has been maximised, generally for a period of 4 to 10 days.
  • a preferred level of each addition of the carboxylic acid or derivative thereof is between 0.05 and 4.0 g/L.
  • the best yields of the compounds from formulae 1_ or 2 are generally by gradually adding the acid or derivative to the fermentation, for example by daily addition over a period of several days.
  • the medium used for the fermentation may be a conventional complex medium containing assimilable BOU ⁇ C ⁇ S of carbon, nitrogen and trace elements.
  • step 1 of Scheme 1 the C-9 carbonyl, of formula 1_, is converted to the corresponding oxim ⁇ at the C-9 position by reacting the macrolide with hydroxylamine or preferably, a hydroxylamine salt such as a hydrochloride.
  • At least one molar equivalent is usually employed in a weakly basic, tertiary amine (preferably pyridine) as a solvent; at a temperature range 20-80°C.
  • a protic solvent such as methanol
  • a base such as barium carbonate
  • the preferred conditions employ an excess, (2-4 molar equivalents) of an orgnic sulfonyl chloride, preferably p-t ⁇ luene-sulfonyl chloride, which is reacted with the oxi e, as free base or acid salt) in a mixture of a lower ketone, such as methyl ethyl ketone or acetone, and water containing a large molar excess of sodium bicarbonate, at a temperature of 0-50°C, preferably at 0-30°C.
  • a lower ketone such as methyl ethyl ketone or acetone
  • step 3 or Scheme 1 Imlno ether, of formula 3, is reduced to a mixture of the laotam, of formula 4, and the azalide, of formula 5.
  • a reducing agent such as an organo-metallic catalyst such as platinum oxide in an acid solvent such as glacial acetic acid under a minimum of 50 psi hydrogen pressure.
  • a preferred method for the production of 5 incorporates the u ⁇ e of boron reduoing reagents such as sodium borohydride, generally used in excess, 2-10 equivalents, in protic solvents such as methanol or ethylene glycol, at a temperature range of -5-40 ⁇ C, preferably 0-20°C.
  • boron reduoing reagents such as sodium borohydride, generally used in excess, 2-10 equivalents
  • protic solvents such as methanol or ethylene glycol
  • azalide, of formula 5 is converted to formula 6 via reductive methylatlon, using a methylating agent such as formaldehyde in the presence of a reducing agent, preferably formic acid.
  • a methylating agent such as formaldehyde
  • a reducing agent preferably formic acid.
  • the preferred method requires at least one molar equivalent each of formaldehyde and formic acid in an inert solvent such as chloroform at 20-100°C, preferably at 30-60°C.
  • step 1 of Scheme 2 the C-9 carbonyl, of formula J , is converted to the corresponding oxime at the C-9 position by reacting the macrolide with hydroxylamine or preferably, a hydroxylamine salt such as a hydrochloride.
  • hydroxylamine or preferably, a hydroxylamine salt such as a hydrochloride.
  • a protic solvent such as methanol
  • a base such as barium carbonate
  • step 3a of Scheme 2 oxime, of formula 2a, is rearranged to the corresponding imlno ether via a Beckman rearrangement as outlined In J. Chem. Soc. Perki ⁇ Trans. I, I9 ⁇ , 1181.
  • the preferred conditions employ an excess, 2-4 molar equivalents) of an orgnic sulfonyl chloride, preferably p-toiuene-sulfonyl chloride, which is reacted with the oxime, as free base or acid salt) in a mixture of a lower ketone, such as methyl ethyl ketone or acetone, and water containing a large molar excess if sodium bicarbonate, at a temperature of 0-50 p C, preferably at 0-30°C.
  • a lower ketone such as methyl ethyl ketone or acetone
  • step 4a of Scheme 2 imino ether, of formula 3a, is reduced to the azalide, of formula 5a.
  • a reducing agent such as an organo- meialllc catalyst such as for example, platinum oxide
  • an acid solvent such as glacial acetic acid under a minimum of 50 psi hydrogen pressure.
  • a preferred method for the production of incorporates the use of boron reducing reagents such as sodium borohydride, generally used in excess, 2-10 equivalents, in protic solvents such as methanol or ethylene glycol, at a temperature range of -5-40"C, preferably 0-20°C.
  • azalide, of formula 5a is converted to formula 6a via reductive methylation, using a methylating agent such as formaldehyde, in the presence of a reducing agent, preferably formic acid.
  • a methylating agent such as formaldehyde
  • a reducing agent preferably formic acid.
  • the preferred method requires at least one molar equivalent each of formaldehyde and formic acid in an inert solvent such as chloroform at 20- 100°C, preferably at SO- ⁇ o'O.
  • the C-2' hydroxy group may be selectively protected by treating the compound of formula ) with one equivalent of acetic anhydride in dichlorometha ⁇ e in the absence of external base to provide the compound of formula 1_1 wherein R is acetyl.
  • the acetyl protecting group may be removed by treating the compound of formula V ⁇ _ with methanol at 23 - 65 °C for about 10 to about 48 hours.
  • the C-2' hydroxy may also be protected with other protecting groups such as the benzyloxycarbonyl (Cbz) group using methods familiar to those skilled in the art.
  • the C-9a amino group may also require protection when Y is H before further synthetic modifications are performed.
  • Suitable protecting groups for the amino moiety are Cbz and t-butyloxycarbonyl (Boc) groups.
  • the macrolide may be treated with t-butyl dicarbonate in anhydrous tetrahydrofuran (THF) or benzyloxycarbonyl N-hydroxysuccinimide ester or benzylchloroformate to protect the amino group as its t-butyl or benzyl carbamate.
  • THF tetrahydrofuran
  • benzyloxycarbonyl N-hydroxysuccinimide ester or benzylchloroformate to protect the amino group as its t-butyl or benzyl carbamate.
  • Both the C-9a and the C-2' bydroxy may be selectively protected with the Cbz group in one step by treating the compound of formula 1J3, where Y is a hydrogen, with benzylchloroformate in THF and water.
  • the Boc group may be removed by acid treatment and the Cbz group may be removed by conventional catalytic hydrogenation.
  • the C-9a amino moiety and the C-2' hydroxy group are protected and deprotected as would be deemed appropriate by one skilled in the art.
  • step 2 of Scheme 3A the C-4" hydroxy group of the compound of formula 1_1 is oxidized to the corresponding ketone, formula _12, by methods familiar to those skilled in the art
  • Compounds of formula 14 can be generated by treating compounds of formula 2 with R 19 MgX ⁇ or R 19 -Li and Mg(X 1 ) 2 .
  • X 1 is a halide such as chloro or bromo, in a solvent such as THF, ethylene glycol, dimethyl ether (DME), diisopropyl ether, toluene, diethyl ether, or tetramethylethylenediamine (TMEDA), or a mixture of the foregoing solvents, preferably an ether solvent, at a temperature ranging from about -78°C to about room temperature (20- 25°C).
  • a solvent such as THF, ethylene glycol, dimethyl ether (DME), diisopropyl ether, toluene, diethyl ether, or tetramethylethylenediamine (TMEDA), or a mixture of the foregoing solvents, preferably an ether solvent, at a temperature ranging from about -78°C to about room temperature (20- 25°C).
  • Scheme 3B Illustrates the preparation of compounds of formula 14 using an epoxide intermediate.
  • the compound of formula __3 may be generated by two methods.
  • a base such as potassium tert-butoxide, sodium ethoxide, sodium hydride, 1,1,3,3-tetramethylguanidine, 1 ,8-diazabicyclo[5.4.0]undec-7-ene, 1,5- diazabicylo[4.3.0]n ⁇ n-5-ene, potassium ethoxide, or sodium methoxide, preferably a sodium- containing base such as sodium hydride, in a solvent such as THF, an ether solvent, dimethylformamide (DMF), or methyl solfoxide (DMSO), or a mixture of the foregoing solvents, at
  • the compound of formula 13 is generated in which the following configuration of the epoxide moiety may predominate:
  • the compound of formula 13 may be converted to a compound of formula 14 wherein R 1B is hydroxy and R 19 is a group that is attached to the C-4" carbon through a methyi ⁇ ne group, such as where R 19 is -CH 2 N ⁇ R a or -CH z S( ⁇ ) n R 8 wherein n, R 6 , and R ⁇ are as defined above.
  • the compound of formula 13 may be treated with a compound of formula HNR ⁇ R 8 , wherein R 6 and R 8 are as defined above, in the absence or presence of a solvent such as water, methanol, or THF, or a mixture of the foregoing solvents, at a temperature ranging from about room temperature to about 100°C, preferably 60°C, optionally in the presence of a metal halide such as potassium iodide, pyridinium hydrochloride, or tetraalkylammonium haiide reagent such as benzene or toluene at a temperature ranging from about room temperature to about 120°C.
  • a solvent such as water, methanol, or THF, or a mixture of the foregoing solvents
  • step 1 of Scheme 4 the C-9 carbonyl, of formula
  • hydroxylamine or preferably, a hydroxylamine salt such as a hydrochloride.
  • at least one molar equivalent, usually an excess, 5-10 equivalents is usually employed in a weakly basic, tertiary amine (preferably pyridine) as a solvent; at a temperature range 20-80°C.
  • a protic solvent such as methanol, can also be used in conjunction with a base, such as barium carbonate, to provide a weakly basic solvent.
  • the oxime of formula 6 may be reduced to the corresponding imine by treating with a metal halide such at TiCl 3 in an acetate buffered solvent such as methanol or ethanol, methanol preferred.
  • a metal halide such at TiCl 3
  • an acetate buffered solvent such as methanol or ethanol, methanol preferred.
  • Reduction is also possible with divalent vanadium (prepared by Zn/Hg/HCI reduction of vanadyl sulphate) in a protic organic solvent such as methanol or ethanol, methanol preferred.
  • the imine of formula 17 may be reduced to the corresponding amine, of formula Iji, by various methods familiar to those skilled in the art.
  • a preferred method incorporates the use of boron reducing reagents such as sodium borohydride, generally used in excess, 2-10 equivalents, in protic solvents such as methanol or ethylene glycol, at a temperature range of -5-40°C, preferably 0-20°C.
  • the compounds of the present invention may have asymmetric carbon atoms and therefore exist in different enantiomeric and diastereomeric forms.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization.
  • Ena ⁇ tiomers may be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., alcohol
  • the compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to mammals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
  • the desired salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.
  • Those compounds of the present invention that are acidic in nature are capable of forming base salts with various cations.
  • base salts include the alkali metal or alkaline-earth metal salts and particularly the sodium, amine and potassium salts. These salts are all prepared by conventional techniques.
  • the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention.
  • Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium, magnesium, various amine cations, etc.
  • These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable bases with cations such as sodium, potassium, calcium, magnesium, various amine cations, etc., and then evaporating the resulting solution to dryness, preferably under reduced pressure.
  • they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness In the same manner as before.
  • stoichi ⁇ metric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
  • the activity of the compounds of the present invention against bacterial and protozoa pathogens is demonstrated by the compound's ability to inhibit growtn of defined strains of human (Assay I) or animal (Assays II and 111) pathogens.
  • Assay I Assay I, descnbed below, employs conventional methodology and interpretation criteria and is designed to provide direction for chemical modifications that may lead to compounds that circumvent defined mechanisms of macrolide resistance.
  • Assay I a panel of bacterial strains is assembled to include a variety of target pathogenic species, including representatives of macrolide resistance mechanisms that have been characterized.
  • Bacterial pathogens that comprise the screening panel are shown in the table below in many cases, both the macrolide-susceptible parent strain and the macrolide-resistant strain derived from it are available to provide a more accurate assessment of the compound's ability to circumvent the resistance mechanism.
  • Strains that contain the gene with the designation of ormAAtrmBfermC are resistant to macrolides, lincosamides, and streptogramin B antibiotics due to modifications (methylation) of 23S rRNA molecules by an Erm methylase, thereby generally prevent the binding of all three structural classes.
  • msrA encodes a component of an efflux system in staphylococci that prevents the entry of macrolides and streptogramins while m ⁇ fA/E encodes a transmembrane protein that appears to efflux only macrolides.
  • Inactivation of macrolide antibiotics can occur and can be mediated by either a phosphorylation of the 2'-hydroxyl (mph) or by cleavage of the macrocyclic lactone (esterase)
  • the strains may be characterized using conventional polymerase chain reaction (PCR) technology and/or by sequencing the resistance determinant The use of PCR technology in this application is described in J.
  • Assay II is utilized to test for activity against Pasteurella multocida and Assay III is utilized to test for activity against Pasteurella haemolytica.
  • Assay II This assay is based on the liquid dilution method in microtiter format. A single colony of
  • P. mult ⁇ ida (strain 59A067) is inoculated into 5 ml of brain heart infusion (BHl) broth.
  • the test compounds are prepared by solubilizing 1 mg of the compound in 125 ⁇ l of dimethylsulfoxide (DMSO). Dilutions of the test compound are prepared using uninoculated BHl broth. The concentrations of the test compound used range from 200 ⁇ g/ml to 0.098 ⁇ g/ml by two-fold serial dilutions.
  • the P. multocida inoculated BHl is diluted with uninoculated BHl broth to make a 10 4 cell suspension per 200 ⁇ l.
  • the BHl cell suspensions are mixed with respective serial dilutions of the test compound, and incubated at 37°C for 18 hours.
  • the minimum inhibitory concentration (MIC) Is equal to the concentration of the compound exhibiting 100% inhibition of growth of P. multocida as determined by comparison with an uninoculated control.
  • This assay Is based on the agar dilution method using a Steers Replicator. Two to five colonies isolated from an agar plate are inoculated into BHl broth and incubated overnight at 37°C with shaking (200 rpm). The next morning, 300 ⁇ l of the fully grown P. haemolytica preculture is inoculated into 3 ml of fresh BHl broth and is incubated at 37 D C with shaking (200 rpm). The appropriate amounts of the test compounds are dissolved in ethanol and a series of two-fold serial dilutions are prepared. Two ml of the respective serial dilution is mixed with 18 ml of molten BHl agar and solidified. When the inoculated P.
  • haemolytica culture reaches 0.5 McFarland standard density, about 5 ⁇ l of the P. haemolytica culture is inoculated onto BHl agar plates containing the various concentrations of the test compound using a Steers Replicator and incubated for 18 hours at 37 C. initial concentrations of the test compound range from 100-200 ⁇ g/ml. The MIC is equal to the concentration of the test compound exhibiting 100% inhibition of growth of P. haemolytica as determined by comparison with an uninoculated control.
  • the jn yj o activity of the compounds of formula (I) can be determined by conventional animal protection studies well known to those skilled in the art, usually carried out in mice. Mice are allotted to cages (10 per cage) upon their amval, and allowed to acclimate for a minimum of 48 hours before being used. Animals are inoculated with 0.5 ml of a 3 x 10 3 CFU/ml bacterial suspension (P. multocida strain 59A006) intrapentoneally. Each experiment has at least 3 non-medicated control groups including one infected with 0.1X challenge dose and two infected with 1X challenge dose; a 10X challenge data group may also be used.
  • mice in a given study can be challenged within 30-90 minutes, especially if a repeating syringe (such as a Cornwall® syringe) is used to administer the challenge. Thirty minutes after challenging has begun, the first compound treatment is given. It may be necessary for a second person to begin compound dosing if all of the animals have not been challenged at the end of 30 minutes.
  • the routes of administration are subcutaneous or oral doses. Subcutaneous doses ere administered into the loose skin in the back of the neck whereas oral doses are given by means of a feeding needle In both cases, a volume of 02 ml is used per mouse Compounds are administered 30 minutes, 4 hours, and 24 hours after challenge. A control compound of known efficacy administered by the same route is included in each test. Animals are observed daily, and the number of survivors in each group is recorded. The P. multocida model monitoring continues for 96 hours (four days) post challenge.
  • the PDso is a calculated dose at which the compound tested protects 50% of a group of mice from mortality due to the bacterial infection which would be lethal in the absence of drug treatment.
  • the compounds of formula 1, 11, S and 0 and the pharmaceutically acceptable salts thereof may be adminstered through oral, parenteral, topical, or rectal routes in the treatment of bacterial and protozoa infections.
  • these compounds are most desirably administered in dosages ranging from about 0.2 mg per kg body weight per day (mg/kg/day) to about 200 mg/kg/day in single or divided doses (i.e., from 1 to 4 doses per day), although variations will necessanly occur depending upon the species, weight and condition of the subject being treated and the particular route of administration chosen.
  • a dosage level that is in the range of about 4 mg/kg/day to about 50 mg/kg/day is most desirably employed, Vanations may nevertheless occur depending upon the species of mammal, fish or bird being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is earned out.
  • dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects, provided that such larger doses are first divided into several small doses for administration throughout the day.
  • the active compounds may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by the routes previously indicated, and such administration may be carried out in single or multiple doses.
  • the active compounds may be administered in a wide variety of different dosage forms, I.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules. lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like.
  • Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc.
  • oral pharmaceutical compositions can be suitably sweetened and/or flavored.
  • the active compounds are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.
  • tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably com, potato or tapioca starch), alginic acid and certain complex silicatea, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia, Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
  • compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials In this connection also include lactose or milk sugar as well as high molecular weight polyethylene ⁇ lycols.
  • preferred materials In this connection also include lactose or milk sugar as well as high molecular weight polyethylene ⁇ lycols.
  • the active compound When aqueous suspensions and/or elixirs are desired for oral administration, the active compound may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • solutions of an active compound in either sesame or peanut oil or in aqueous propylene glycol may be employed.
  • the aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic.
  • These aqueous solutions are suitable for intravenous injection purposes,
  • the oily solutions are suitable for intraarticular. intramuscular and subcutaneous injection purposes.
  • the preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques will known to those skilled in the art.
  • the active compounds of the present invention may be administered topically and this may be done by way of creams, jellies, gels, pastes, patches, ointments and the like, in accordance with standard pharmaceutical practice.
  • the active compounds may be administered in the feed of the animals or orally as a drench composition.
  • the active compounds may also be adminstered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phosphollplds, such as cholesterol, stearylamine or phosphatidylcholines.
  • the active compounds may also be coupled with soluble polymers as targetable drug carriers.
  • soluble polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylam.de phenyl, polyhydroxyethylaspartamide-phenol. or polyethyleneoxide-potylysine substituted with palmitoylre ⁇ idue ⁇ .
  • the active compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polygtycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolacto ⁇ e, polyhydroxy butyric acid, polyorthoesters. polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • Example 1-1 400 mg of the corresponding macrolide of formula _1_, where R 1 is isopropyl and R 2 is H, was dissolved in 8 mL of anhydrous pyridine. Hydroxylamine hydrochloride (0.2B5 g, 7.5 equiv.) was added and the solution heated to 60" C and stirred Tor 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted 3 x 25 mL methylene chloride, and dried over Na 2 S0 4 . Filtration and concentration of filtrate yielded a light yellow solid product. The product (0.403 g) was carried on to the next step without further purification. Preparation for Example 1-2 (Table 1)
  • Example 1-3 Preparation for Example 1-3 (Table 1) 250 mg of the corresponding macrolide of formula 1_, where R 1 is see-butyl and R 2 is H, was dissolved in 5 mL of anhydrous pyridine. Hydroxylamine hydrochloride (0.175 g, 7.5 equiv.) was added and the solution heated to 60° C and stirred for 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted 3 x 25 mL methylene chloride, and dried over NaaSO «, Filtration and concentration of filtrate yielded a light yellow solid product. The product (0.246 g) was carried on to the next step without further purification.
  • Hydroxylamine hydrochloride 0.175 g, 7.5 equiv.
  • Example 1-4 Preparation for Example 1-4 (Table 1) 250 mg of the corresponding macrolide of formula 1, where R 1 is cyclobutyl and R 2 is H, was dissolved in 5 mL of anhydrous pyridine. Hydroxylamine hydrochloride (0.175 g, 7.5 equiv.) was added and the solution heated to 60" C and stirred for 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1 N NaOH. extracted 3 x 25 mL methylene chloride, and dried over Na 2 S0 . Filtration and concentration of filtrate yielded a light yellow solid product. The product (0.249 g) was carried on to the next step without further purification.
  • Hydroxylamine hydrochloride 0.175 g, 7.5 equiv.
  • Example 1-6 Preparation for Example 1-6 (Table 1) 95 mg of the corresponding macrolide of formula 1_, where R 1 is methylthioethyl and R 2 is H, was dissolved in 1.9 mL of anhydrous pyridine. Hydroxylamine hydrochloride (0.065 g, 7.5 equiv.) was added and the solution heated to 60° C and stirred for 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted 3 x 25 mL methylene chloride, and dried over Na 2 S0 4 . Filtration and concentration of filtrate yielded a light yellow solid product. The product (0.091 g) was carried on to the next step without further purification.
  • Hydroxylamine hydrochloride 0.065 g, 7.5 equiv.
  • Example 1-8 (Table 1) 4.9(3 g of the corresponding macrolide of formula 1_, where R 1 Is cyclobutyl and R 2 Is OH. was dissolved in 50.0 mL of anhydrous pyridine. Hydroxylamine hydrochloride (3.4 g. 7.5 equjv.) was added and the solution heated to 60° C and stirred for 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted 3 x 25 mL methylene chloride, and dried over Na S j. Filtration and concentration of filtrate yielded a light yellow solid product. The product (4.24 g) was carried on to the next step without further purification.
  • Hydroxylamine hydrochloride 3.4 g. 7.5 equjv.
  • Example 2-7 Preparation for Example 2-7 (Table 2) 60 mg of the corresponding oxime of formula 2, where R 1 is cyclopropyl and R 2 is OH, was dissolved in 1 mL of acetone. A 0.1 M aqueous solution of Na 2 HC0 3 (0.027 g in 0.5 mL water) was added and the resulting mixture was cooled to 0° C. A solution of para- toluenesulfonyl chloride (0.031 g) in acetone (0.5mL). cooled to 0° C, was added and the mixture stirred overnight The reaction was worked up by decanting into 25 L of a 1:1 mixture of methylene chloride and water.
  • Preparation 4 An amount of 11-250 mg of the corresponding imidate of formula 3 was dissolved in THF and ethylene glycol then cooled to 0-5° C. NaBH 4 (5-10 equiv.) was added and the reaction stirred tor 4 hours at 0-5 6 C and then warmed to room temperature. The reaction was worked up by decanting into 10 mL of a 1:1 mixture of methylene chloride and water. The aqueous was re-extracted 3 x 5 mL methylene chloride. The organic layers were combined and dried over Na 2 S0 4 . Filteration and concentration yielded a solid product
  • Example 3-1 (Table 3) 150 mg of the corresponding imidate of formula 3, where R 1 is isopropyl and R 2 is H, was dissolved in 3.75 mL tetrahydrofuran and 7.5 mL ethylene glycol and then cooled to 0-5° C. Na ⁇ H 4 (0.039 g) was added and the reaction stirred for 6 hours at 0-5° C and then warmed to room temperature. The reaction was worked up by decanting into 10 mL of a 1:1 mixture of methylene chloride and water. The aqueous was re-extracted 3 x 5 mL methylene chloride. The organic layers were combined and dried over Na z S0 4 . Filteration and concentration yielded a solid product (0.1 9 g).
  • Example 3-2 165 mg of the corresponding imidate of formula 3, where R 1 is cyclopropyl and R 2 is H, was dissolved In glacial acetic acid (20 mL) . Platinum oxide catalyst (0.026 g, 50 mole %) was added, the reaction flushed with nitrogen, placed under 50 psi hydrogen and shaken at room temperature for 24 hours. Additional platinum oxide catalyst (50 mole %) was added, the reaction flushed with nitrogen, placed under 50 psi hydrogen and shaken at room temperature for additional 24 hours. Reaction was worked up by filteration through CeliteTM.
  • Example 3-4 (Table 3) 250 mg of the corresponding imidate of formula 3, where R 1 cyclobutyl and R 2 is H, was dissolved in 3.83 mL tetrahydrofuran and 5.0 mL ethylene glycol and then cooled to 0-5 p C. NaBH 4 (0.191 g) was added and the reaction stirred for 6 hours at 0-5° C and then warmed to room temperature. The reaction was worked up by decanting into 10 mL of a 1:1 mixture of methylene chloride and water. The aqueous was re-extracted 3 x 5 L methylene chloride. The organic layers were combined and dried over Na 2 S0 4 . Filteration and concentration yielded a solid product (0.201 g).
  • T e nmr data for compounds included within those of formula 5 is shown in Tables 3A and 38 below.
  • Preparation 6 The corresponding oxime of formula 2 is dissolved in ethanol. Lithium hydroxide monohydrate (2 equivalents) is added and the reaction mixture stirred ovemight at room temperature. The reaction is concentrated under vacuum and partitioned between brine and ethyl acetate, the pH of the reaction mixture is adjusted to 9-10, the reaction mixture is extracted with ethyl acetate, and dried over Na 2 S0 4 . A 4:1 ratio of Z:E isomers is produced. Isolation of isomers is accomplished by either silica chromatography or crystallization from nitromethane.
  • Preparation 7 The corresponding oxime of formula 2a is dissolved in acetone. A 0.1 M aqueous solution of Na g HCO a (2 equiv.) is added and the resulting mixture is cooled to 0-5° C. A 0.1 M solution of para-toluenesulfonyl chloride in acetone is added and the mixture stirred overnight. The reaction is worked up by decanting into 25 mL of a 1:1 mixture of methylene chloride and water. The pH of the reaction mixture is adjusted to 9-10 using 1N NaOH, the reaction mixture is extracted with 3 x 20 mL methylene chloride, and dried over Na 2 S0 4 . Filtration and concentration of filtrate yields a solid product. The product is carried on to the next step without further purification. Table 7
  • Preparation 9 The corresponding imidate of formula 3a is dissolved in 0.5 mL MeOH and cooled to 0-5° C. NaBH 4 (10 equiv.) is added and the reaction stirred for 4 hours at 0-5° C, warmed to room temperature, and stirred ovemight. The reaction is worked up by decanting into 10 mL of a 1:1 mixture of methylene chloride and water, the pH of the reaction mixture adjusted to ⁇ -g using i N NaOH, extracted 3 x 5 mL methylene chloride, and dried over Na-jSO,. Filtration and concentration yields a solid product Purification is accomplished by HPLC.
  • Preparation 10 The corresponding azalide of formula 5 ⁇ is dissolved in chloroform. 37% formaldehyde (1.0 equiv.) and formic acid (1.0 equiv.) is added and the solution stirred at 45-50° C for 48-72 hours. The reaction mixture is then decanted into a 1:1 mixture of chloroform and water, the pH of the reaction mixture is adjusted to 9-10 using 1N NaOH, the reaction mixture is extracted with chloroform, and dried over Na 2 S0 4 . Filtration and concentration yields a solid product. Isolation of product is accomplished by either silica chromatography or HPLC.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention relates to novel erythromycin analogs and azalides, particularly ones with novel C-13 substituents, and to pharmaceutically acceptable salts thereof. The compounds of this invention are antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention also relates to pharmaceutical compositions containing such compounds and to methods of treating bacterial protozoa infections by administering such compounds. The invention also relates to methods of preparing such compounds and to intermediates useful in such preparation.

Description

NOVEL MACROLIDES
Background of the Invention This invention relates to novel erythromycins and azalides that are useful as antibacterial agents and antiprotozoa agents and other applications (e.g , anticancer, atherosclerosis, gastric mo lity reduction, etc.) in mammals, including man, as well as in fish and birds. This invention also relates to pharmaceutical compoβitions containing the novel compounds and to methods of treating bacterial infections and protozoa infections and in mammals, fish and birds by administering the novel compounds to mammals, fish and birds requiring such treatment
Macrolide antibiotics are known to be useful In the treatment of a broad sprectrum of bacterial infections and protozoa infections in mammals, fish and birds. Such antibiotics include various derivatives of erythromycin A such as azithromycin which is commercially available and is referred to in United States patents 4,474,758 and 4,517,359, both of which are incorporated herein by reference in their entirety. Additional macrolides are referred to in U.S. patent application serial number 60/063676, filed October 29, 1597 (Yong-Jin Wu), U.S appiication serial number 60/063161, filed October 29, 1997 (Yong-Jin Wu), U.S. application serial number 60/054866, filed August 6, 1997(Hiroko Masamune, Yong-Jin Wu, Takushi Kaneko and Paul R. cGuirk), U.S. application serial number 60/049980, filed June 11 , 1997 (Brian Θ. Bronk, Michael A. Letavic, Takushi Kaneko and Bingwel V. Yang), U.S. application serial number 60/049348, filed June 11. 1997 (Brian S. Bronk, Hensmiao Cheng, E. A Glaεer, Michael A. Letavic, Takushi Kaneko and Bingwei V. Yang), International Application No. PCT/GB97/01810 filed July 4, 1997 (Peter Francis Leadlay, James Staunton, Jesus Cortes and Michael Stephen Pacey), International Application No. PCT/GB97/01819 filed July 4, 1997 (Peter Francis Leadlay, James Staunton, and Jecuc Cortβe), U.S. application serial no, 60/070343, filed January 2, 1998, (Diriam), U.S. application serial no, 60/070358, filed January 2, 1998 (Yong-Jin Wu) and U.S. application serial no. 60\097075, filed August 19, 1998 (Heπgrniao Cheng, Michael A. Letavic, Carl B. Ziegier, Jason K, Dutra, Bnan S. Bronk), all of which are incorporated herein by reference in their entirety. Like azithromycin and other macrolide antibiotics, the novel macrolide compounds of the present invention possess potent activity against various bacterial infections and protozoa infections as described below. Summary of the Invention The present invention relates to compounds of the formula
Figure imgf000004_0001
or a pharmaceutically acceptable salt thereof, wherein: Y is H, d-Cio alkyl, c2-C-|0 alkenyl, c2-c10 alkynyl, -(CH2)mcβ-c10aryl, -(CH2)m(5-io membered heteroaryl). wherein m is an inteoer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl groups are optionally substituted by 1 to 3 subεtituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(0)RZ1, -OC(0)R21, - NR21C(0)R22, -C(0)NR21R22, -NR21R22, hydroxy, C,-C6 alkyl, CrCβ alkoxy, C6-C10 aryl, and 5- 10 membered heteroaryl;
R1 is an alpha-branched Cj-C8 alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a Cs-Cβ cycloalkylalkyl group wherein the alkyl group is an alpha-branched C C5 alkyl group; a C,-C3 cycloalkyl or C5-C„ cycloalkeπyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more C,-C alkyl groups or halo atoms: or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more 0,-0-, alkyl groups or halo atoms; or R1 is phenyl which may be optionally substituted with at least one substituent selected from C,-C4 alkyl, C,-C4 alkoxy and CrC4 alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano; or R1 may be with a formula (a) as shown below:
Figure imgf000005_0001
wherein X is O, S or -CH2-, a, b, c, and d are each independently an integer ranging from 0 to 2 and a + b ♦ c + d < 5; or R1 is CH2R2*, wherein R24 is H, C.-Caalkyl, C2-C8alkenyl, C2-Cβalkynyl, alkoxyalkyl or alkylihloalkyl containing from 1 to s carbon aioms In each alkyl or alkoxy group wherein any of said alkyl. alkoxy. alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a (VCβcycloalkyl or C3-CBcycloalkenyl either or which may be optionally substituted by methyl or one or more C,-C4alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated or fully or partially unsaturated and which may optionally be substituted by one or more d-C^alkyl groups or halo atoms; or a group of the formula SR43 wherein R23 is Cn- C8alkyl, C2-C„alkenyl, C2-C8a|kynyl, C3-CBcycloalkyl, C8-Cgcycloalkenyl, phenyl or substituted phenyl wherein the substituent is CrC4alkyl, CrC4alkoχy or halo, or a 3 to 6 membered oxygen or sulphur-containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C C4alkyl groups or halo atoms;
R2 is H or OH; R9 is H, OH, or OCH3;
R4 is H, -C(0)R9, -C(0)OR9, -C(0)NR8 R10 or a hydroxy protecting group; R5 is -SR8, -(CH2)nC(0)Rβ wherein n is 0 or 1 , C,-C10 alkyl, C2-C10 alkenyl, C2-
C10 alkynyl, -(CH2)m(C6-C10 aryl), or -(CH2)m(5-lθ membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R5 groups are optionally substituted by 1 to 3 1e groups; each R6 and R7 is independently H, hydroxy, CrCs alkoxy, CrC, alkyl, C2-Cβ alkenyl, C2-C6 alkynyl, -(CH2)m(C6-C10 aryl), or -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4; each RB is independently H, CrC10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, -(CH2)e(CR11R1z(CH2)l.NR13R1* wherein q and r are each independently an integer ranging from 0 to 3 except q and r are not both 0, -(CH2)m(Cβ-Cι0 aryl), or -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing Rβ groups, except H, are optionally substituted by 1 to 3 R1β groups; or where Ra is as -CH2NRβR15, R15 and Rβ may be taken together to form a 4-10 membered moπocycllc or poiycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S and -N(R8)-, in addition to the nitrogen to which R16 and R8 are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R16 groups; each Rβ and R10 is independently H or C,-Cβ alkyl; each R11, R12, R13 and R14 is independently selected from H, C,-C10 alkyl, -(CHi)m(Cβ- C10 aryl), and -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R11, R12, R13 and R14 groups, except H, are optionally substituted by 1 to 3 R16 groups; or R1 and R1 are taken together to form -(CHZ)P- wherein p is an integer ranging from
0 to 3 such that a 4-7 membered saturated ring is formed that optionally includes 1 or 2 carbon-carbon double or triple bonds; or R S and R14 are taken together to form a 4-10 membered monocyclic or poiycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein 3aid saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S and -N(RB)-, in addition to the nitrogen to which R13 and R14 are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R1s groups;
R1S is H. Cι-C,6 alkyl, Ca-C10 alkenyl. Or Cz-C,_ alkynyl, wherein the foregoing R1S groups are optionally substituted by 1 to 3 substituents independently selected from halo and - OR9; each R1B is independently selected from halo, cyano, nitro, trifluoromethyl, azido, - C(0)R17, -C(0)OR17, -C(0)OR17, -OC(0)OR17, -NR6C(0)R7, -C(0)NR8R7, -NR6R7, hydroxy, C-rCg alkyl, C|-C8 alkoxy, -(CH2)m(C6-C10 aryl), and -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein said aryl and heteroaryl subsituents are optionally substituted by 1 or 2 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(0)Rl7, -C(0)OR17, -C(0)OR'7, -OC(0)OR17, -NR6C(0)R7, - C(0)NR6Rr, -NRβR7. hydroxy. C--C. alkyl. and C C. alkoxy: each R17 is independently selected from H, C C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, -(CH2)m(Ce-C10 aryl), and -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, provided that Ra is not H where R1β is -CH2S(0)nRe; R1, is OH;
R 9 is CrC,o alkyl, C2-C10 alkenyl, C2-C,0 alkynyl, cyano, -CHjS(O)0R8 wherein n is an integer ranging from 0 to 2, -CH2ORe, -CH2N(OR9)Re, -CH2NR*R15, -(CH2)m(Ce-C,Q aryl), or - (CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R10 groups are optionally substituted by i to 3 R1β groups; or R1β and R19 are taken together to form an oxazolyl ring as shown below
Figure imgf000007_0001
and; each R21 and R22 is independently H, hydroxy, CrCβ alkoxy, C,-Cβ alkyl, C2-Cβ alkenyl, (CHz)m(C6-C1D) aryl, (CH2)m(5-1θ membered heteroaryl), wherein m Is an integer ranging from 0 to 4, or C2-C|o alkylyl.
The present invention further relates to compounds of the formula
Figure imgf000007_0002
or a pharmaceutically acceptable salt thereof, wherein:
Y is H, Ct-C10 alkyl, C2-C10 alkenyl, Cz-Cl0 alkynyl, -(CH2)mC6-Cl0aryl, -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(0)R2\ -OC(0)R21, - NR21C(0)R22, -CfOJN ^R22, -NR2lRa hydroxy, C,-C6 alkyl, C,-C6 alkoxy, CB-C,0 aryl, and 5- 10 membered heteroaryl; R1 Is an alpha-branched C3-C8 alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C3-Cβ cycloalkylalkyl group wherein the alkyl group is an alpha-branched C2-C5 alkyl group, a C C8 cycloalkyl or C5-C„ cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more d-C-, alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more d-d alkyl groups or halo atoms; or R1 is phenyl which may be optionally substituted with at least one substituent selected from CrC4 alkyl, C C4 alkoxy and CrC4 alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano; or R1 may be with a formula (a) as shown below:
Figure imgf000008_0001
wherein X is O, S or -CH2-, a, b, c, and d are each independently 0-2 and a + b + c + d < 5; or R1 is CHtR24, wherein R24 is H, C,-CBalkyl, d-Cβalkenyl, C CBalkynyl, alkoxyalkyl or alkylthioalkyl containing from 1 to 6 carbon atoms in each alkyl or alkoxy group wherein any of said alkyl, alkoxy, alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a C3-Cβcycloalkyl or C5-CBcycloalkenyl either or which may be optionally substituted by methyl or one or more CrC4alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated or fully or partially unsaturated and which may optionally be substituted by one or more C,-C4alkyl groups or halo atoms; or a group of the formula SR23 wherein R23 is C-,- CBaikyl, c2-CBalkenyl, C2-C8alkynyl, c3-cacycloalkyl, C3-C8cyc|oalken l, phenyl or substituted phenyl wherein the substituent is CrC alkyl, CrC4alkoxy or halo, or a 3 to 6 membered oxygen or sulphur-containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C C alkyl groups or halo atoms;
Rz is H or OH; R3 is H, OH, or OCH3; R4 is H, -C(0)R9, -C(0)ORB, -C(0)NR9R10 or a hydroxy protecting group; each R9 and R19 is independently H or d-d alkyl; R" is OH; R" Is H and; each R21 and R22 is independently H, hydroxy, CrC„ alkoxy, CrCs alkyl, C2-C6 alkenyl, (CH2)m(C8-C,o) aryl, (CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, or C2-Cl0 al ytyl.
The compounds of formula I are exemplified by the compounds of formulas 5 and 6, described below, wherein Y mH and CH3, respectively.
Preferred compounds of formula include those wherein R1 = isopropyl, sec-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methylthioethyl and 3-furyl.
The compounds of formula II are exemplified by the compounds of formulas 6 and 6a, described below, wherein Y =H and CH3, respectively. Preferred compounds of formula II include those wherein R1 = isopropyl, sec-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methylthioethyl and 3-furyl.
Other preferred compounds of formula I and formula II include those wherein R^is
Figure imgf000009_0001
and R1 is isopropyl, R2 is H and R1β is OH;
R1 is isopropyl, R2 is OH and R19 is OH;
R1 is cyclopropyl, R2 is H and R19 is OH;
R1 is cyclopropyl, Rz is OH and R1β is OH;
R1 is sec-butyl, R2 is H and R1β is OH; R1 is sec-butyl, R2 is OH and R19 is OH;
R1 Is cyclobutyl, R2 Is H and R19 Is OH;
R1 is cyclobutyl, R2 is OH and R19 is OH;
R1 is cyclopentyl, R2 is H and R19 is OH;
R1 is cyclopentyl, R2 is OH and R1β is OH; R1 is methylthioethyl, Rz is H and R19 is OH;
R1 is methylthioethyl, R2 is OH and R1β is OH;
R1 is 3-furyl, R2 is H, R19 is OH and or
R1 is 3-furyl, R2 is OH and R19 is OH.
The invention further relates to compounds of the 2, 2a, 3, 3a, 4, 5, 6, 7, 8, 9, 10, 11. 12. H. H. J!, .16. 17 and 18. The invention further relates to a compound of the formula
Figure imgf000010_0001
or a pharmaceutically acceptable salt thereof, wherein.
R1 is an alpha-branched d-d alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C5-C3 cycloalkylalkyl group wherein the alkyl group is an alpha-branched C2-C3 alkyl group; a C3-C3 cycloalkyl or C5-C.3 cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more d-d alkyl groups or halo atoms: or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C,-C4 alkyl groups or halo atoms; or R1 is phenyl which may be optionally substituted with at least one substituent selected from CrC4 alkyl, C,-C4 alkoxy and C,-C4 alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano; or R may be with a formula (a) as shown below:
Figure imgf000010_0002
wherein X is 0, S or -CH2-, a, b, c, and d are each independently 0-2 and a + b + c + d < 5, or R1 is CH2R24, wherein R*4 is H, C,-CBalkyl, C2-CBalkenyl, C2-C8alkynyl, alkoxyalkyl or alkylthioalkyl containing from 1 to 6 carbon atoms in each alkyl or alkoxy group wherein any of said alkyl, alkoxy, alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a C3-C8cycloalkyl or CrC8cycloalkenyl either or which may be optionally substituted by methyl or one or more C,-C4alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated or fully or partially unsaturated and which may optionally be substituted by one or more Cι-C4alkyl groups or halo atoms; or a group of the formula SR23 wherein R23 Is C,- dalkyl, C2-CBalkenyl, C2-Caalkynyl, C C8cycloalkyl, Cs-dcycloalkenyl, phenyl or substituted phenyl wherein the substituent is C -C4a]kyi, C,-C alkoxy or halo, or a 3 to 6 membered oxygen or sulphur-containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more CrC4alkyl groups or halo atoms; and
R2 is H or OH.
The invention further relates to a compound of the formula
Figure imgf000011_0001
or a pharmaceutically acceptable salt thereof, wherein: R1 is an alpha-branched C3-CB alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C3-C8 cycloalkylalkyl group wherein the alkyl group is an alpha-branched C2-C3 alkyl group; a C3-C8 cycloalkyl or d-C, cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more d-d alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C,-d alkyl groups or halo atoms; or R' is phenyl which may be optionally substituted with at least one substituent selected from C,-C4 alkyl, C,-d alkoxy and C,-C4 alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano; or R, may be with a formula (a) as shown below:
Figure imgf000012_0001
wherein X is O, S or -CHZ-, a, b, o, and d are each independently 0-2 and a + b + c * d < 6; or R1 is CHj-R24, wherein R24 is H, C,-C8alkyl, C2-C8alkenyl, C2-CBalkynyl, alkoxyalkyl or alkylthioalkyl containing from 1 to 6 carbon atoms in each alkyl or alkoxy group wherein any of said alkyl, alkoxy, alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a Ca-Cβcycloalkyl or C3-C8cycloalkenyl either or which may be optionally substituted by methyl or one or more C,-C4alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated or fully or partially unsaturated and which may optionally be substituted by one or more d-C4alkyl groups or halo atoms; or a group of the formula SR23 wherein R23 is C Cβalkyl, d-dalkenyl, C2-Cβalkynyl, C_,-Cβcydoalkyl, Ca-C„cycloalkenyl, phenyl or substituted phenyl wherein the substituent is C.-C alkyl, d-C4alkoxy or halo, or a 3 to 6 membered oxygen or sulphur-containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more d-dalkyl groups or halo atoms;and R2 is H or OH.
The invention also relates to a pharmaceutical composition for the treatment of a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises a therapeutlcally effective amount of a compound of formulas I, II, 8, or 9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention also relates to a method of treating a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises administering to said mammal, fish or bird a therapeutically effective amount of a compound of formula I, II, 8, or 9, or a pharmaceutically acceptable salt thereof. The invention also relates to a process for preparing a compound of the formula
Figure imgf000013_0001
wherein R1 and R2 are as defined for the compound of formula I, which comprises treating a compound of the formula
Figure imgf000013_0002
wherein R1 and R2 are as defined for the compound of formula I, with a reducing agent
The invention also relates to the above process wherein the reducing agent is NaBH4 or platinum oxide. The invention also relates to a process for preparing a compound of the formula
Figure imgf000014_0001
wherein R1 and R2 are as defined for the compound of formula I, which comprises treating a compound of the formula
Figure imgf000014_0002
wherein R* and R2 are as defined for the compound of formula I, with a methylating agent.
Trie Invention also relates to the above process wherein the methylating agent Is formaldehyde. The invention also relates to a process for preparing a compound of the formula
Figure imgf000015_0001
wherein R1 and R2 are as defined for the compound of formula I, which comprises treating a compound of the formula
Figure imgf000015_0002
wherein R1 and R2 are as defined for the compound of formula I, with a reducing agent.
The invention also relates to the above process wherein the reducing agent is NaBH4 or platinum oxide. The invention also relates to a process for preparing a compound of the formula
Figure imgf000016_0001
wherein R1 and R2 are as defined for the compound of formula I, which comprises treating a compound of the formula
Figure imgf000016_0002
wherein R1 and R2 are as defined for the compound of formula I, with a methylating agent.
The Invention also relates to tha above process wherein the methylating agent is formaldehyde. The invention also relates to a compound of the formula
Figure imgf000017_0001
or a pharmaceutically acceptable salt thereof, wherein:
Y is H, d-C.o alkyl, C2-C10 alkenyl, C2-C10 alkynyl, -(CH2)mC6-C10aryl, -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(0)R21, -OC(0)R21, - NR21C(0)R22, -C(0)NR21R2Z, -NR 1R22, hydroxy, d-C3 alkyl, d- alkoxy, C6-C1Q aryl, and 5- 10 membered heteroaryl;
R1 is an alpha-branched C3-C„ alkyl. alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a CS-CB cycloalkylalkyl group wherein the alkyl group is an alpha-branched d-d alkyl group; a d-d cycloalkyl or C3-C8 cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more CrC4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C alkyl groups or halo atoms; or R1 is phenyl which may be optionally substituted with at least one substituent selected from d-C4 alkyl, CrC4 alkoxy and C C alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano; or R1 may be with a formula (a) as shown below:
Figure imgf000018_0001
wherein X is O, 3 or -CH2-, a, b, c, and d are each independently an integer ranging from 0 to 2 and a + b + c + d < 5; or R1 is CH2R24, wherein R24 is H, C,-C8alkyl, C2-Cβalkenyl, C2-C9alkynyl, alkoxyalkyl or alkylthioalkyl containing from 1 to 6 carbon atoms in each alkyl or alkoxy group wherein any of said alkyl, alkoxy, alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a C3-Cβcycloalkyl or C5-Cβcycloalkenyl either or which may be optionally substituted by methyl or one or more C,-C4alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated or fully or partially unsaturated and which may optionally be substituted by one or more C,-C4alkyl groups or halo atoms; or a group of the formula SR23 wherein R23 is C,- dalkyl, C2-Cβalkenyl, C2-C8alkyπyl, C3-CBcycloalkyl, CB-CBcycloalkenyl, phenyl or substituted phenyl wherein the substituent is CrC4alkyl, C.-C4alkoxy or halo, or a 3 to 6 membered oxygen or sulphur-containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C1-C4alkyl groups or halo atoms;
R2 is H or OH; R3 is H, OH, or OCH3;
R4 is H, -C(0)R9, -C(0)OR*, -C(0)NR* R1β or a hydroxy protecting group; R6 is -SR8, -(CH2)„C(0)R8 wherein n is 0 or 1, C,-C10 alkyl, C2-C10 alkenyl, C2- do alkynyl, -(CH2)m(Cβ-C,o aryl), or -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing Rs groups are optionally substituted by 1 to 3 R18 groups; each R aπd R7 is independently H, hydroxy, 0,-08 alkoxy, 0-,-Cβ alkyl, C2-C6 alkenyl, C2-C„ alkynyl, -(CH2)rτι(C6-C10 aryl), or -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4; each R* is independently H, 0,-0,6 alkyl, drdo alkenyl, C2-C10 alkynyl, -(CH2)qCR11R1ϊ(CH2)rNR1sR14 wherein q and r are each independently an integer ranging from 0 to 3 except q and r are not both 0, -(CH2)m(Cβ-C10 aryl), or -(CHj)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R8 groups, except H, are optionally substituted by 1 to 3 R1β groups; or where R" is as -CH2NRβR1β, R1D and RB may be taken together to form a 4-10 membered monocyclic or poiycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S and -N(R8)-, in addition to the nitrogen to which R15 and RB are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R1s groups; each R9 and R10 is independently H or C,-C8 alkyl; each
Figure imgf000019_0001
R a, R11 and Ru Is independently selected from H, C,-C,0 alkyl, -(CH2) C5-
C,0 aryl), and -(CHj)m(5-10 membered heteroaryl), wherein is an integer ranging from 0 to 4, and wherein the foregoing R1 , R12, R13 and R groups, except H, are optionally substituted by 1 to 3 R16 groups; or R11 and R13 are taken together to form -(CH2)p- wherein p is an integer ranging from 0 to 3 such that a 4-7 membered saturated ring is formed that optionally includes 1 or 2 carbon-carbon double or triple bonds; or R13 and R14 are taken together to form a 4-10 membered monocyclic or poiycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally Include 1 or 2 heteroatoms selected from O, S and -N(RB)-, In addition to the nitrogen to which R13 and Rt4 are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R 6 groups;
R1S is H, d-C1p alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, wherein the foregoing RlS groups are optionally substituted by 1 to 3 substituents independently selected from halo and - ORθ; each R1S is independently selected from halo, cyano, nitro, trifluoromethyl, azido, - C(0)R17, -C(0)OR17, -C(0)OR17, -OC(0)OR17, -NR6C(0)R7, -C(0)NR6R7, -NR6R7, hydroxy, C,-C6 alkyl, CrC6 alkoxy, -(CH2)m(C6-C10 aryl), and -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein said aryl and heteroaryl subsituents are optionally substituted by 1 or 2 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(0)R17, -C(0)OR17, -C(0)OR17, -OC(0)OR17, -NRβC(0)R7, - C(0)NRβR7, -NRβR7, hydroxy. C,-Ce alkyl, and CrC8 alkoxy; each R17 is independently selected from H, C C 0 alkyl, Cj-C1D alkenyl, Ci-C1β alkynyl, -(CH2)m(d-do aryl), and -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, provided that Rβ is not H where R19 is -CH2S(0)nRB; R1Bis OH;
R19 is d-C10 alkyl, CrC10 alkenyl, C2-C1Q alkynyl, cyano, -CH2S(0)nRB wherein π is an integer ranging from 0 to 2, -CH20R8, -CH2N(ORβ)Rβ, -CH2NRBR15, -(CHa) -do aryl), or - (CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R1B groups are optionally substituted by 1 to 3 R16 groups; or R1a and R19 are taken together to form an oxazolyl ring as shown below
Figure imgf000020_0001
and; each R21 and R22 is independently H, hydroxy, d-CB alkoxy, C,-C6 alkyl, C2-C6 alkenyl, (CH2)m(C6-C 0) aryl, (CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, or C2-C10 alkylyl.
The term "treatment" , as used herein, unless otherwise indicated, includes the treatment or prevention of a bacterial infection or protozoa infection as provided in the method of the present invention.
As used herein, unless otherwise indicated, the term "bacterial infection(s)" or "protozoa infections; includes bacterial infections and protozoa infections that occur in mammals, fish and birds as well as disorders related to bacterial infections and protozoa infections that may be treated or prevented by administering antibiotics such as the compounds of the present invention. Such bacterial infections and protozoa infections and disorders related to such infections include the following; pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxalla catarrhalis, Staphylococcus aureus, or Pβptostreptococcus spp.; pharynigitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Clostridium diptheriaβ, or Actinobacillus haβmolytlcum; respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chlamydia pneumoniae; uncomplicated skin and soft tissue infections, abscesses and osteomyelitis, and puerperal fever related to infection by Staphylococcus aureus, coagulase- positive staphylococci (i.e., S. epidβrmidis, S. hemolyticus, etc.), Streptococcus pyogenes , Streptococcus agalactiaβ, Streptococcal groups C-F (minute-colony streptococci), viridans streptococci, Corynβbactβήum minutissimum, Clostridium spp., or Bartonβlla hβnselae; uncomplicated acute urinary tract infections related to infection by Staphylococcus saprophytlcus or Enterococcus spp.; urethritis and cervicitis; and sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus dυcrβyi, Trβponβma pallidum, Ureaplasma urealyticu , or Naisβrria gonorrhβae; toxin diseases related to infection by S. aureus (food poisoning and Toxic shock syndrome), or Groups A, B, and C streptococci; ulcers related to infection by Hθllcobactβr pylori: systemic febrile syndromes related to WO 99/35156 _ ι g_ PCT/IB98/02099
infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorfβn; conjunctivitis, keratitis, and dacrocystitis related to infection by Chlamydia trachomatis, Neisseήa gonorrhoeaβ, S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, or Listβria spp.; disseminated Mycobactβrium avium complex (MAC) disease related to infection by Mycobacterium avium, or Mycobacterium intracellulare; gastroenteritis related to infection by Cdmpyl bβctør jβjυni; intestinal protozoa related to infection by Cryptospoπdium spp.; odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by Bordetella pertussis; gas gangrene related to infection by Clostridium perfήngens or Bacteroides spp.; and atherosclerosis related to infection by Helicobacter pylon or Chlamydia pneumoniae. Bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in animals include the following: bovine respiratory disease related to infection by P. haβm., P. multocida, Mycoplasma bows, or Bordetella spp.; cow enteric disease related to infection by E. coll or protozoa (i.e., coccidia, cryptosporidia, etc.); dairy cow mastitis related to infection by SfapΛ. aureus, Strep, uberis, Strep, agalβctiβe, Strep, dysgβlβctiae, Klebaiella spp,, Corynebβcterium, or ntβrococoua spp.; swine respiratory disease related to infection by A. pleuro., P. multocida, or Mycoplasma spp.; swine enteric disease related to infection by E. coli, Lawsonia intracellularis, Salmonella, or Serpulina hyodyisinteriae; cow footrot related to infection by Fusobacterium spp.; cow metπtis related to infection by _z. con; cow hairy warts related to infection by Fusobacterium necrophorum or Bacteroides nodosus: cow pink-eye related to infection by Moraxalla boυis; cow premature abortion related to infection by protozoa (i.e. neosporium); urinary tract infection in dogs and cats related to infection by £ coli; skin and soft tissue infections in dogs and cats related to infection by Staph. epidermidis, Staph. intβrmedius, coagulasβ nβg. Staph. or P. multocida; and dental or mouth infections in dogs and cats related to infection by Alcaligenes spp., Bacteroides spp., Clostridium spp., Enterobacter spp., Eubacterium, Peptostreptococcus, Poφhyromonas, or Prevotella. Other bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in accord with the method of the present invention are referred to in J. P. Sanford et al., "The Sanford Guide To Antimicrobial Therapy." 26th Edition. (Antimicrobial Therapy, Inc., 1996).
The present invention also relates to a method of preparing the above compounds of formulas I, II, 8, or 9. The compounds used in the preparation of the compounds of formulas I, II, 8, and 9 can prepared using the methods described in International Application No. PCT/GB97/01810 filed July 4, 1997 (Peter Francis Leadlay, James Staunton, Jesus Cortes and Michael Stephen Pacey), and International Application No. PCT/GB97/01819 tiled July 4, 1997 (Peter Francis Leadlay, James Staunton, and Jesus Cortes), both of which are is incorporated herein by reference in their entirety. The present Invention also relates to the compounds of formulas 2, 2a, 3^ 3a, and 4 to
23 which, are useful in the preparation of the above compounds of formulas I, II, 8 and 9 and pharmaceutically acceptable salts thereof.
The term "hydroxy protecting group", as used herein, unless otherwise indicated, includes acetyl, benzyloxycarbonyl, and various hydroxy protecting groups familiar to those skilled in the art include the groups referred to in T. W. Greene, P. Q. M. Wuts, "Protective Groups In Organic Synthesis," (J. Wiley & Sons, 1991),
The term "halo", as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo.
Trie term "alkyr, as used herein, unless otherwise Indicated, includes saturated monovalent hydrocarbon radicals having straight, cyclic or branched moieties, or mixtures thereof. It is to be understood that where cyclic moieties are intended, at least three carbons in said alkyl must be present Such cyclic moieties include cyclopropyl, cyclobutyl and cyclopentyl.
The term "alkoxy", as used herein, unless otherwise indicated, includes -O-alkyl groups wherein alkyl is as defined above.
T e term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.
The term "5-10 membered heteroaryl", as used herein, unless otherwise indicated, includes aromatic heterocyclic groups containing one or more heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 5 to 10 atoms in its ring system. Examples of suitable 5-10 membered heteroaryl groups include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, (1 ,2,3,)- and (1 ,2,4)-triazolyl, pyra-zinyl, tatrazolyl, furyl, thionyl, isoxazolyl, oxazolyl, pyrrolyl and thiazolyl, The phrase "pharmaceutically acceptable salt(s)", as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be present in the compounds of the present invention. The compounds of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of the present invention are those that form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable anlons, such as the hydrochlorlde, hydrobromlde, hydrolodlde, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, paπtothenate, bitartrate, ascorbate, succiπate, maleate, gentisinate, fumarate, gluconate, glucaronatβ, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfoπate, p-toluenesulfonate and pamoate [i.e., l ,l'-methylene-bis-(2- hydroxy-3-πaphthoate)) salts, The compounds of the present invention that include an amino moiety may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above.
Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline earth metal salts and, particulariy, the calcium, magnesium, sodium and potassium salts of the compounds of the present invention.
Certain compounds of the present invention may have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms. This invention relates to the use of all optical Isomers and stereolsomers of the compounds of the present invention, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment that may employ or contain them.
The present invention includes the compounds of the present invention, and the pharmaceutically acceptable salts thereof, wherein one or more hydrogen, carbon or other atoms are replaced by isotopes thereof. Such compounds may be U3eful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays.
Detailed Description of the Invention The compounds of of the present invention may be prepared according to Schemes 1-4 below and trie description that follows, in the following Schemes, unless otherwise indicated, substituents R,, ?, R3, R4, Rs, R„, R7, R„, Rβ, R10, R„, RUι R„, R,4ι R19 R1βι R17ι R1Bι R1β| R20ι and Y are as defined above.
Scheme 1
Figure imgf000024_0001
Figure imgf000024_0002
scheme 1 continued
Figure imgf000025_0001
Figure imgf000025_0002
Scheme 1 Continued
Figure imgf000026_0001
Figure imgf000026_0002
Scheme 2
2a
Figure imgf000027_0001
Scheme 2 Continued
Figure imgf000028_0001
5a
Figure imgf000028_0002
Scheme 3A
Figure imgf000029_0001
Scheme 3B
Figure imgf000030_0001
Figure imgf000030_0002
Scheme 4
Figure imgf000031_0001
Figure imgf000031_0002
Scheme 4 Continued
Figure imgf000032_0001
Figure imgf000032_0002
The compounds of the present invention are readily prepared. The compounds used in the preparation of the compounds of formulas I, II, 8, and 9 can prepared using the methods described in International Appiication No. PCT/GB97/01810 filed July 4, 1997 (Peter Francis Leadlay, James Staunton, Jesus Cortes and Michael Stephen Pacey), and International Application No. PCT/GB97/01819 filed July 4, 1997 (Peter Francis Leadlay, James Staunton, and Jesus Cortes), both of which are Is Incorporated herein by reference in their entirety.
The novel polyketides and methods and means for preparing them, and specifically the novel macrolides that are useful in the preparation of the compounds of the present invention are prepared by fermenting suitable organisms in the presence of
Figure imgf000033_0001
where R1 is as defined in claim 1 or claim 2. A preferred organism is Saccharopolyspora erythraea preferably containing an integrated plasmid capable of directing synthesis of desired compounds, In producing such novel polyketides, polyketide biosynthetic genes or portions of them, which may be derived from different polyketide biosynthetic gene clusters are manipulated to allow the production of novel erythromycins,
Polyketides are a large and structurally diverse class of natural products that includes many compounds possessing antibiotic or other pharmacological properties, such as erythromycjπ, tetracyclines, rapamycin, avermectin, polyether ionophores, and FK5D6. In particular, polyketides are abundantly produced by Streptomyces and related actinomycete bacteria. They are synthesised by the repeated stepwise condensation of acylthioesters in a manner analogous to that of fatty acid biosynthesis, The greater structural diversity found among natural polyketides arises from the selection of (usually) acetate or propionate as "starter" or "extender" units; and from the differing degree of processing of the β-keto group observed after each condensation. Examples of processing steps include reduction to β-hydroxyacyl-, reduction followed by dehydration to 2-enoyl-, and complete reduction to the saturated acylthioester. The stereochemieal outcome of these processing steps is also specified for each cycle of chain extension. The biosynthesis of polyketides is initiated by a group of chain-forming enzymes known as polyketide synthases. Two classes of polyketide synthase (PKS) have been described in actinomycetes. However, the novel polyketides and processes which are used in preparing the compounds the present invention are synthesised by Type I PKS's, represented by the P S's for the macrolides erythromycin, avermectin and rapamycin, and consist of a different set or "module" of enzymes for each cycle of polyketide chain extension (Cortes, J. et al. Nature (1990) 348:176-178; Donadio, S. et al. Science (1991) 252:675-679; acNeil, D. J. et al. Gene (1992), 115:119-125; Schwecke, T. et al. Proc. Nati. Acad, Sci. USA (1995) 92:7839-7843), Note: The term "natural module" as used herein refers to the set of contiguous domains, from a β-ketoacylsynthase ("KS") gene to the next acyl carrier protein ("ACP") gene, which accomplishes one cycle of polyketide chain extension. The term "combinatorial module" is used to refer to any group of contiguous domains (and domain parts), extending from a first point in a first natural module, to a second equivalent point in a second natural module. The first and second points will generally be in core domains which are present in all modules, i.e., both at equivalent points of respective KS, AT (acyl transferase), ACP domains, or in linker regions between domains. T e organisation of the erythromycin producing PKS, (also known as β- deoxyerythronolide B synthase, DEBS) genes contains three open reading frames encode the DEBS polypeptides. The genes are organised in six repeated units designated modules. The first open reading frame encodes the first multi-enzyme or cassette (DEBS1) which consists of three modules: the loading module (ery_-load) and two extension modules (modules 1 and 2). The loading module comprises an acyl transferase and an acyl carrier protein. This may be contrasted with Figure 1 of W093/13663 (referred to below). This shows ORF1 to consist of only two modules, the first of which is in fact both the loading module and the first extension module. ln-frame deletion of the DNA encoding part of the ketoreductase domain of module 5 in DEBS has been shown to lead to the formation of erythromycin analogues 5,6-dideoxy-3-mycarosyl-5-oxoerythronolide B, 5,6-dideoxy-5-oxoerythronolide B and 5,6-dideoxy-6,6-epoxy-5-oxoerythronolide B (Donadio, S. et al. Science, (1991) 252:675-679). Likewise, alteration of active site residues in the enoylreductase domain of module 4 in DEBS, by genetic engineering of the corresponding P S-encoding DNA and its introduction into Saccharopolyspora erythraea, led to the production of 6,7-anhydroerythromycin C (Donadio S. et al. Proc. Nati. Acad, Sci. USA (1993) 90:7119-7123).
International Patent Application number WO 93/13663, which is incorporated herein by reference In Its entirely, describes additional types of genetic manipulation of the DEBS genes that are capable of producing altered polyketides. However, many such attempts are reported to have been unproductive (Hutchinson C. R. and Fujii, I. Annu. Rev. Microbiol. (1995) 49:201-238, at p.231). The complete DNA sequence of the genes from Streptomyces hygroscopi'cus that encode the modular Type 1 PKS governing the biosynthesis of the macrocyclic immunoβuppreβsant polyketide rapamycin has been disclosed (Schwβckβ, T. et al. (1995) Proc. Nati, Acad. Sci. USA 92:7839-7843). The DNA sequence is deposited in the E BIJGeπbank Database under the accession number X86780.
The complex polyketides produced by modular Type I PKS's are particularly valuable, in that they include compounds with known utility as anthelminthics, insecticides, immunosuppressants, antifungal, and/or antibacterial agents. Because of their structural complexity, such novel polyketides are not readily obtainable by total chemical synthesis, or by chemical modifications of known polyketides. As described in International Application PCT/GB97/01810, the Type I PKS gene assembly encodes a loading module which is followed by extension modules. It is particularly useful to provide a hybrid PKS gene assembly in which the loading module is heterologous to the extension modules and is such as to lead to a polyketide having an altered starter unit. As noted in in International Application PCT/GB97/01810, this is a concept quite unknown to the prior art since this does not recognise the existence of loading modules. W093/13863 refers to altering PKS genes by inactivating a single function (i.e. a single enzyme) or affecting "an entire module" by deletion, insertion, or replacement thereof. The loading assembly, in their terms, is not a module.
If the loading module is one which accepts many different carboxylic acid units, then the hybrid gene assembly can be used to produce many different polyketideβ. For example, a hybrid gene assembly may employ nucleic acid encoding an avr loading module with ery extender modules. A loading module may accept unnatural acid units and derivatives thereof, the avr loading module is particulariy useful in this regard (Duttoπ et al,, (1991) J. Antibiot., 44:357-365). In addition, it Is possible to determine the specificity of the natural loading module far unnatural starter units and to take advantage of the relaxed specificity of the loading module to generate novel polyketides. Thus, International Application PCT/GB97/01810 describes the unexpected ability of the ery loading module to incorporate unnatural carboxylic acids and derivatives thereof to produce novel erythromycins in erythromycin-producing strains containing only DEBS genes. Of course one may also make alterations within a product polyketide particularly by replacing an extension module by one that gives a ketide unit at a different oxidation state and/or with a different stereochemistry. It has generally been assumed that the stereochemistry of the methyl groups in the polyketide chain Is determined by the a cy .transferase, but it is, in fact, a feature of other domains of the PKS and thus open to variation only by replacement of those domains, individually or by module replacement. Methyl and other substituents can be added or removed by acyltransferase domain replacement or total module replacement. Consequently, it also becomes apparent to those skilled in the art that it is possible to combine the use of the relaxed substrate specificity of the erythromycin loading module with extension module replacement and hybrid leading module substitution with extension module replacement as a mechanism to produce a wide range of novel erythromycins. Thus, International Application PCT/GB97/01810 describes the production of novel erythromycins by non-transformed organisms and also such gene assemblies, vectors containing such gene assemblies, and transformant organisms that can express them to produce novel erythromycins in transformed organisms. Transformant organisms may harbour recombinant plasmids, or the plasmids may integrate. A plasmid with an int sequence will integrate into a specific attachment site (att) of a host's chromosome. Transformant organisms may be capable of modifying the initial products, e.g., by carrying out all or some of the biosynthetic modifications normal in the production of erythromycins. However, use may be made of mutant organisms such that some of the normal pathways are blocked, e.g., to produce products without one or more "natural" hydroxy-groups or sugar groups, for instance as described in WO 91/16334 or in Weber et al. (1985) J. Bacterlol. 164:425-433 hich are Incorporated herein by reference in their entirety. Alternatively, use may be made of organisms in which some of the normal pathways are overexpressed to overcome potential rate-limiting steps in the production of the desired product, for instance as described in WO 97/06266 which is incorporated herein by reference in its entirety. This aspect of the method is largely concerned with treating PKS gene modules as building blocks that can be used to construct enzyme systems, and thus novel erythromycin products, of desired types. This generally involves the cutting out and the assembly of modules and multi-module groupings. Logical places for making and breaking intermodular connections are be In the linking regions between modules. However, it may be preferable to make cuts and joins actually within domains (i.e., the enzyme-coding portions), close to the edges thereof. The DNA is highly conserved here between all modular PKS's, and this may aid in the construction of hybrids that can be transcribed. It may also assist in maintaining the spacing of the active sites of the encoded enzymes, which may be important For example, in producing a hybrid gens by replacing the er loading module by an avr loading module, the ery module together with a small amount of the following ketosynthase (KS) domain was removed. The start of the KS domain (well spaced from the active site) is highly conserved and therefore provides a suitable splicing site as an alternative to the linker region between the loading domain and the start of the KS domain. The excised er^ module was then replaced by an avr loading module. In fact, when substituting a loading module, it may be desirable to replace not just the loading module domains (generally acyl transferase (AT) and acyl carrier protein (ACP)), but also the KS at the start of the following extension module. Typically, the excised loading module would have provided a propionate starter, and the replacement is intended to provide one or more different starters. Propionate, however, may feed into the KS of the extension module from a propionate pool in the host cell, leading to dilution of the desired products. This can be largely prevented by substituting an extended loading module including all or most of the KS domain. (The splice site may be in the end region of the KS gene, or early in the following AT gene, or the linker region between them.)
When replacing "modules", one is not restricted to "natural" modules. For example, a "combinatorial module" to be excised and/or replaced and/or inserted may extend from the corresponding domain of two natural-type modules, e.g., from the AT of one module to the AT of the next, or from KS to KS. The splice sites will be in corresponding conserved marginal regions or in linker regions. A combinatorial module can also be a 'double' or larger multiple, for adding 2 or more modules at a time.
International Application PCT/GB97/01810 describes novel erythromycins obtainable by means of tne previous aspects. These Include the following:
(i) An erythromycin analogue (being a macrolide compound with a 14-membered ring) in which a substituent R, on the C-13 position, bears a side-chain other than ethyl, generally a straight chain C3-C6 alkyl group, a branched C3-C8 alkyl group, a C3-C8 cycloalkyi or cycloalkenyl group (optionally substituted, e.g., with one or more hydroxy, C-)_ alkyl or alkoxy groups or halogen atoms), or a 3-6 membered heterocycle containing O or S, saturated or fully or partially unsaturated, optionally substituted (as for cycloalkyi), or R is phenyl which may be optionally substituted with at least one substituent selected from C,-C4 alkyl, C1-C alkoxy and C,-C4 alkylthio groups, halogen atoms, trifluoromethyl, and cyano; or R may be a group with a formula (a) as shown below:
Figure imgf000038_0001
wherein X is 0, S or -CH2-, a, b, c, and d are each independently 0-2 and a + b + c + d 5. Preferred candidateβ for the C-13 substituent R are the groups of carboxylate units RCOOR', usable as substrates by an avr starter module, or rapamycin starter variants. Preferred substrates are the carboxylic acids RCOOH. Alternative substrates that can be effectively used are carboxylic acid salts, carboxylic acid esters, or amides. Preferred esters are N- acetyl-cysteamiπe thioesters which can readily be utilised as substrates by the avr starter module as illustrated by Dutton et al. in EP 0350187 which is incorporated herein by reference in its entirety. Preferred amides are N-acyl imidazoles. Other alternative substrates that may be used are derivatives which are oxidative precursors for the carboxylic acids; thus, for example suitable substrates would be amino acids of the formula RCH(NH2)COOH, glyoxylic acids of the formula RCOCOOH, methylamine derivatives of the formula RCHaNHa, methanol derivatives of the formula RCH2OH, aldehydes of the formula RCHO or substituted alkanoie acids of the formula R(CH2)nCOOH wherein n is 2, 4, or 6. Thus examples of preferred substrates include isobutyrate (Risi-Pr) and 2-methylbutyrate (Ris1-methylpropyl). Other possibilities include n-butyrate, cyclopropyl carboxylate, cyclobutyl carboxylate, cyclopentyl carboxylate cyclohexyl carboxylate, cycloheptanyl carboxylate, cyclohexenyl carboxylates, cycloheptenyl carboxylates, and ring-methylated variants of the cyclic carboxylates and the aforementioned derivatives thereof,
The erythromycin analogue may correspond to the initial product of a PKS (6- daoxyerythranolide) or the product after one or more of the normal biosynthetic steps. These comprise: 6-hydroxylation; 3-0-glycosylation; 5-0-glycosylation; 12-hydroχylation; and specific sugar ethylation.
Thus, the analogues may include those corresponding to 6-deoxyerythronoiide B, erythromycin A, and various intermediates and alternatives thereof. (ii) Erythromycin analogues differing from the corresponding 'natural' in the oxidation state of one or more of the ketjde units (i.e. selection of alternatives from the group: -CO-, - CH(OH)-. IsCH-. and -CH -).
The stereochemistry of any -CH(OH)- is also independently selectable.
(iii) Erythromycin analogues differing from the corresponding 'natural' compound in the absence of a 'natural' methyl side-chain. (This Is achievable by use of a variant AT). Normal extension modules use either C2 or C3 units to provide unmethylated and methylated ketlde units. One may provide unmethylated units where methylated units are natural (and vice versa, in systems where there are naturally unmethylated units) and also provide larger units, e.g., C4 to provide ethyl substituents.
(iv) Erythromycin analogues differing from the corresponding 'natural' compound in the stereochemistry of 'natural' methyl; and/or ring substituents other than methyl.
(v) Erythromycin analogues having the features of two or more of sections (i) to (iv). (vi) Derivatives of any of the above which have undergone further processing by non-
PKS enzymes, e.g., one or more of hydroxylation, epoxidation, glycosylation, and methylation.
International Application PCT/GB97/01810 describes methods for the production of the novel erythromycins useful in the preparation of the compounds of the present invention.
In the simplest method, unnatural starter units (preferably, but not restricted to the carboxylic acid analogues or the unnatural starter units) are introduced to untransformed organisms capable of producing erythromycins. A preferred approach involves introduction of the starter unit into fermentation broths of the erythromycin-producing organism, an approach which is more effective for transformed organisms capable of producing erythromycins. However, the starter unit analogue can also be introduced to alternative preparations of the erythromycin- producing organisms, for example, fractionated or unfractionated broken-cell preparations. Again, this approach is equally effective for transformed organisms capable of producing erythromycins. In another method, one or more segments of DNA encoding individual modules or domains within a heterologous Type I PKS (the "donor" PKS) have been used to replace the DNA encoding, respectively, individual modules or domains within the DEBS genes of an erythromycin-producing organism. Loading modules and extension modules drawn from any natural or non-natural Type I PKS, are suitable for this "donor" PKS but particularly suitable for this purpose are the components of Type I PKS's for the biosynthesis of erythromycin, rapamycin, avermectin, tetronasin, oleandomycin, monensin, amphotericin, and rifamycin, for which the gene and modular organisation is known through gene sequence analysis, at least in part. Particularly favourable examples of the loading modules of the donor PKS are those loading modules showing a relaxed specificity, for example, the loading module of the avermectin (avr)-producing PKS of Streptomyces avermitilis; or those loading modules possessing an unusual specificity, for example, the loading modules of the rapamycin-, FK5D6- and ascomycin-producing PKS's. all of which naturally accept a shikimate-derived starter unit. Unexpectedly, both the untransformed and genetically engineered erythromycin-producing organisms when cultured under suitable conditions have been found to produce non-natural erythromycins, and where appropriate, the products are found to undergo the same processing as the natural erythromycin.
International Application PCT/GB97/01810 further describes a plasmid containing "donor" PKS DNA is introduced into a host cell under conditions where the plasmid becomes integrated into the DEBS genes on the chromosome of the erythromycin-producing strain by homologous recombination, to create a hybrid PKS. A preferred embodiment is when the donor PKS DNA includes a segment encoding a loading module in such a way that this loading module becomes linked to the DEBS genes on the chromosome. Such a hybrid PKS produces valuable and novel erythromycin products when cultured under suitable conditions as described herein. Specifically, when the loading module or the DEBS genes Is replaced by the loading module of the avermectin-producing (avr) PKS, the novel erythromycin products contain a starter unit typical of those used by the avr PKS. Thus, when the loading module of the ery PKS is replaced by the avr loading module, Saccharopolyspora erythraea strains containing such hybrid PKS are found to produce 14-membered macrolides containing starter units typically used by the avr PKS,
As noted in International Application PCT/GB97/01810, it is unexpected that the 14-membered macrolide polyketides produced by such recombinant cells of S. erythraea are found to include derivatives of erythromycin A, showing that the several processing steps required for the transformation of the products of the hybrid PKS into novel and therapeutlcally valuable erythromycin A derivatives are correctly carried out. International Application PCT/GB97/01810 describes the unexpected and surprising finding that transcription of any of the hybrid erythromycin genes can be specifically increased when the hybrid genes are placed under the control of a promoter for a Type II PKS gene linked to a specific activator gene for that promoter. It is particulariy remarkable that when a genetically engineered cell containing hybrid erythromycin genes under such control is cultured under conditions suitable for erythromycin production, significantly enhanced levels of the novel erythromycin are produced. Such specific increases in yield of a valuable erythromycin product are also seen ror natural erythromycin PKS placed under the control of a Type II PKS promoter and activator gene. In a preferred embodiment, desired genes present on an SCP2*-derived plasmid are placed under the control of the bidirectional actl promoter derived from the actinorhodin biosynthetic gene cluster of Streptomyces coelicolor, and in which the vector also contains the structural gene encoding the specific activator protein Act ll-orf 4. The recombinant plasmid is introduced into Saccharopolyspora erythraea, under conditions where either the introduced PKS genes, or PKS genes already present in the host strain, are expressed under the control of the actl promoter.
Such strains produce the desired erythromycin product and the activator gene requires only the presence of the specific promoter in order to enhance transcriptional efficiency from the promoter. This is particularly surprising in that activators of the Actll-orf4 family do not belong to a recognised class of DNA-binding proteins. Therefore it would be expected that additional proteins or other control elements would be required for activation to occur in a heterologous host not known to produce actinorhodin or a related isochromanequinone pigment. It is also surprising and useful that the recombinant strains can produce more than ten-fold erythromycin product than when the same PKS genes are under the control of the natural promoter, and the specific erythromycin product is also produced precociously in growing culture, rather than only during the transition from growth to stationary phase, Such erythromycins are useful as antibiotics and for many other purposes in human and veterinary medicine. Thus, when the genetically engineered cell is Saccharopolyspora erythraea, the activator and promoter are derived from the actinorhodin PKS gene cluster and the actl/actll-orf4-regulated ery PKS gene cluster is housed in the chromosome, following the site-specific integration of a low copy number plasmid vector, culturing of these cells under suitable conditions can produce more than ten-fold total 14-membered macrolide product than in a comparable strain not under such heterologous control. When in such a genetically engineered cell of S. erythraea the PKS genes under this heterologous control are hybrid Type I PKS genes whose construction is described herein, more than ten-fold hybrid polyketide product can be obtained compared to the same hybrid Type I PKS genes not under εuch control. Specifically, when the hybrid Type I PKS genes are the ery PKS genes in which the loader module is replaced by the avr loading module, a ten-fold increase is found in the total amounts of novel 14-membered macrolides produced by the genetically engineered cells when cultured under suitable conditions as described in PCT/GB97/01810.
The suitable and preferred means of growing the untransformed and genetically- engineered erythromycin-producing cells, and suitable and preferred means for the isolation, identification, and practical utility of the novel erythromycins are described more fully, in International Application PCT/GB97/01B10.
Erythromycin analogus described in International Application PCT/GB97/01810 are produced by fermentation of an untransformed or transformed organism capable of producing erythromycins, including but not limited to Saccharopolyspora species, Streptomyces griseoplanus, Nocardia sp., Micromonospora sp., Arthobacter sp., and Streptomyces antibioticus, but excluding S. coelicolor. Particularly suitable in this regard are untransformed and transformed strains of Saccharopolyspora erythraea, for example NR L 2338, 18643, 21484. Particularly preferred transformed strains are those in which the erythromycin loading module has been replaced with the loading module from the avermectin producer, Strepbmyces avermitilis, or the rapamycin producer, Streptomyces hygroscopicus. The preferred method of producing compounds of the current invention is by fermentation of the appropriate organism in the presence of the appropriate carboxylic acid of the formula R.,COOH, wherein R, is as defined in formulae 1_ or 2 of International Application PCT/GB97/01810 or is R1 of the compounds of the present invention, or a salt, ester (particularly preferable being the N-acetylcysteamine thioester), or amide thereof or oxidative precursor thereof. The acid or derivative thereof is added to the fermentation either at the time of inoculation or at intervals during the fermentation. Production of the compounds of this invention may be monitored by removing samples from the fermentation, extracting with an organic solvent and following the appearance of the compounds of this invention by chromatography, for example using high pressure liquid chromatography. incubation Is continued untB the yield of the compound of formulae 1_ or 2 has been maximised, generally for a period of 4 to 10 days. A preferred level of each addition of the carboxylic acid or derivative thereof is between 0.05 and 4.0 g/L. The best yields of the compounds from formulae 1_ or 2 are generally by gradually adding the acid or derivative to the fermentation, for example by daily addition over a period of several days. The medium used for the fermentation may be a conventional complex medium containing assimilable BOUΓCΘS of carbon, nitrogen and trace elements.
The wide range of starter units accepted by the avr loading module has been comprehensively established in previous studies (for example European Patent Applications 0 214731, O 350 167, 0 317 148 which are incorporated herein in their entirety). Consequently, it should be understood that the invention is not limited to the specific detail of these examples and simply serve to confirm the effectiveness of the avr loading module. Furthermore, the examples using the pIGIor pND30 construct clearly demonstrate the capability of the actl promoter and its cognate activator gene actll-orf4 to ehance the expression of the novel compounds of this invention when linked to the avr loading module. It is also apparent from the examples that untransformed strains of Saccharopolyspora erythraea are also readily capable of taking up exogenously-supplied substrates to generate novel erythromycin polyketides. Consequently, it is also apparent to those skilled in the art that specific novel compounds of this invention can be readily produced by selection of the appropriate erythromycin producing strain (optionally incorporating the p|G1 or pND30 plasmid into the desired strain), and supplementing the fermentation with the appropriate starter unit Thus, 6- deoxyerythromycin and 6,12-dideoxyerythromycin derivatives of the present invention can be readily produced using Saccharopolyspora erythraea NRRL 18643 or NRRL 21484 as indicated in U.S. 5,141,926 and WO 97/06266. Similarly, use of the Saccharopolyspora erythraea strains described by Weber et al. in J. Bacteriol., 164:425-433, 1991 can also be employed to obtain the desired novel analogues of the present invention. For example, strain UW24 can be used (optionally transformed by plG1 or pND30) to obtain novel analogues of erythronolide B. In step 1 of Scheme 1, the C-9 carbonyl, of formula 1_, is converted to the corresponding oximβ at the C-9 position by reacting the macrolide with hydroxylamine or preferably, a hydroxylamine salt such as a hydrochloride. Under presently preferred conditions, at least one molar equivalent, usually an excess, 5-10 equivalents, is usually employed in a weakly basic, tertiary amine (preferably pyridine) as a solvent; at a temperature range 20-80°C. A protic solvent, such as methanol, can also be used In conjunction with a base, such as barium carbonate, to provide a weakly basic solvent. in step 2 of Scheme 1, oxime, of formula 2, is rearranged to the corresponding imino ether via a Beckman rearrangement as outlined in J. Chem. Soc. Perkiπ Trans. I, 1986, 1181. The preferred conditions employ an excess, (2-4 molar equivalents) of an orgnic sulfonyl chloride, preferably p-tσluene-sulfonyl chloride, which is reacted with the oxi e, as free base or acid salt) in a mixture of a lower ketone, such as methyl ethyl ketone or acetone, and water containing a large molar excess of sodium bicarbonate, at a temperature of 0-50°C, preferably at 0-30°C.
In step 3 or Scheme 1 , Imlno ether, of formula 3, is reduced to a mixture of the laotam, of formula 4, and the azalide, of formula 5. This can be accomplished in various methods familiar to those skilled in the art. One such method is catalytic hydrogenation employing a reducing agent such as an organo-metallic catalyst such as platinum oxide in an acid solvent such as glacial acetic acid under a minimum of 50 psi hydrogen pressure. A preferred method for the production of 5 incorporates the uβe of boron reduoing reagents such as sodium borohydride, generally used in excess, 2-10 equivalents, in protic solvents such as methanol or ethylene glycol, at a temperature range of -5-40βC, preferably 0-20°C.
In step 4 of Scheme 1, azalide, of formula 5, is converted to formula 6 via reductive methylatlon, using a methylating agent such as formaldehyde in the presence of a reducing agent, preferably formic acid. The preferred method requires at least one molar equivalent each of formaldehyde and formic acid in an inert solvent such as chloroform at 20-100°C, preferably at 30-60°C.
In step 1 of Scheme 2, the C-9 carbonyl, of formula J , is converted to the corresponding oxime at the C-9 position by reacting the macrolide with hydroxylamine or preferably, a hydroxylamine salt such as a hydrochloride. Under presently preferred conditions, at least one molar equivalent, usually an excess, 5-10 equivalents, is usually employed in a weakly basic, tertiary amine (preferably pyridine) as a solvent; at a temperature range 20-80°C. A protic solvent, such as methanol, can also be used in conjunction with a base, such as barium carbonate, to provide a weakly basic solvent In step 2a of Scheme 2, oxime, of formula 2, where the olefin geometry is preferentially the "E" isomer is converted to the "Z" isomer in protic solvents such as ethanol using bases of sufficient strength to substantially deprotonate the 9E oxime with small counter ions, such as Li* or Na+, such as lithium hydroxide.
In step 3a of Scheme 2, oxime, of formula 2a, is rearranged to the corresponding imlno ether via a Beckman rearrangement as outlined In J. Chem. Soc. Perkiπ Trans. I, I9ββ, 1181. The preferred conditions employ an excess, 2-4 molar equivalents) of an orgnic sulfonyl chloride, preferably p-toiuene-sulfonyl chloride, which is reacted with the oxime, as free base or acid salt) in a mixture of a lower ketone, such as methyl ethyl ketone or acetone, and water containing a large molar excess if sodium bicarbonate, at a temperature of 0-50pC, preferably at 0-30°C.
In step 4a of Scheme 2, imino ether, of formula 3a, is reduced to the azalide, of formula 5a. This can be accomplished in various methods familiar to those skilled in the art. One such method is catalytic hydrogenation employing a reducing agent such as an organo- meialllc catalyst such as for example, platinum oxide, in an acid solvent such as glacial acetic acid under a minimum of 50 psi hydrogen pressure. A preferred method for the production of incorporates the use of boron reducing reagents such as sodium borohydride, generally used in excess, 2-10 equivalents, in protic solvents such as methanol or ethylene glycol, at a temperature range of -5-40"C, preferably 0-20°C.
In step 5a of Scheme 2, azalide, of formula 5a, is converted to formula 6a via reductive methylation, using a methylating agent such as formaldehyde, in the presence of a reducing agent, preferably formic acid. The preferred method requires at least one molar equivalent each of formaldehyde and formic acid in an inert solvent such as chloroform at 20- 100°C, preferably at SO-θo'O.
In step 1 of Scheme 3A, the C-2' hydroxy group may be selectively protected by treating the compound of formula ) with one equivalent of acetic anhydride in dichloromethaπe in the absence of external base to provide the compound of formula 1_1 wherein R is acetyl. The acetyl protecting group may be removed by treating the compound of formula V\_ with methanol at 23 - 65 °C for about 10 to about 48 hours. The C-2' hydroxy may also be protected with other protecting groups such as the benzyloxycarbonyl (Cbz) group using methods familiar to those skilled in the art. The C-9a amino group may also require protection when Y is H before further synthetic modifications are performed. Suitable protecting groups for the amino moiety are Cbz and t-butyloxycarbonyl (Boc) groups. To protect the C-9a amino group, the macrolide may be treated with t-butyl dicarbonate in anhydrous tetrahydrofuran (THF) or benzyloxycarbonyl N-hydroxysuccinimide ester or benzylchloroformate to protect the amino group as its t-butyl or benzyl carbamate. Both the C-9a and the C-2' bydroxy may be selectively protected with the Cbz group in one step by treating the compound of formula 1J3, where Y is a hydrogen, with benzylchloroformate in THF and water. The Boc group may be removed by acid treatment and the Cbz group may be removed by conventional catalytic hydrogenation. In the following description, it is assumed that the C-9a amino moiety and the C-2' hydroxy group are protected and deprotected as would be deemed appropriate by one skilled in the art.
In step 2 of Scheme 3A, the C-4" hydroxy group of the compound of formula 1_1 is oxidized to the corresponding ketone, formula _12, by methods familiar to those skilled in the art Compounds of formula 14 can be generated by treating compounds of formula 2 with R19MgXι or R19-Li and Mg(X1)2. wherein X1 is a halide such as chloro or bromo, in a solvent such as THF, ethylene glycol, dimethyl ether (DME), diisopropyl ether, toluene, diethyl ether, or tetramethylethylenediamine (TMEDA), or a mixture of the foregoing solvents, preferably an ether solvent, at a temperature ranging from about -78°C to about room temperature (20- 25°C).
Scheme 3B Illustrates the preparation of compounds of formula 14 using an epoxide intermediate. In Scheme 3B, the compound of formula __3 may be generated by two methods. By treating the compound of formula 12 with (CH3)3S(0)Xz, wherein X is halo, -BF4, or PFC, preferably iodo, in the presence of a base such as potassium tert-butoxide, sodium ethoxide, sodium hydride, 1,1,3,3-tetramethylguanidine, 1 ,8-diazabicyclo[5.4.0]undec-7-ene, 1,5- diazabicylo[4.3.0]nθn-5-ene, potassium ethoxide, or sodium methoxide, preferably a sodium- containing base such as sodium hydride, in a solvent such as THF, an ether solvent, dimethylformamide (DMF), or methyl solfoxide (DMSO), or a mixture of the foregoing solvents, at a temperature range of about 0°C to about 60°C, the compound of formula T is generated In which the following configuration of the epoxide moiety may predominate:
Figure imgf000045_0001
By treating the compound of formula \2 with (CHS)3SX3, wherein X3 is halo, -BF«, -PFβ. preferably -BF„ in the presence of a base suchas potassium tert-butoxide, sodium ethoxide, sodium hydride, 1,1,3,3-tetramethylguanidine, 1,8-diazabicylco[5.4.0]undec-7-ene, 1,5- diazabicylo[4.3.0]non-5-ene, potassium ethoxide, potassium t-butoxide, KHMDS or sodium methoxide, preferably KHMDS, In a solvent such as THF. an ether solvent, dimethylformamide (DMF). or methyl sulfoxide (DMSO). or a mixture of the foregoing solvents, at a temperature range of about 0°C to about 60°C, the compound of formula 13 is generated in which the following configuration of the epoxide moiety may predominate:
Figure imgf000046_0001
In step 1 of Scheme 3B, the compound of formula 13 may be converted to a compound of formula 14 wherein R1B is hydroxy and R19 is a group that is attached to the C-4" carbon through a methyiβne group, such as where R19 is -CH2N βRa or -CHzS(θ)nR8 wherein n, R6, and Rβ are as defined above. To prepare a compound of formula 14 wherein R1β is - CH2NR6Rβ, the compound of formula 13 may be treated with a compound of formula HNRβR8, wherein R6 and R8 are as defined above, in the absence or presence of a solvent such as water, methanol, or THF, or a mixture of the foregoing solvents, at a temperature ranging from about room temperature to about 100°C, preferably 60°C, optionally in the presence of a metal halide such as potassium iodide, pyridinium hydrochloride, or tetraalkylammonium haiide reagent such as benzene or toluene at a temperature ranging from about room temperature to about 120°C.
The compounds of scheme 4 can be prepared using substantially the same methods described in U.S. Patent No. 3,681,322, issued August 1. 1972 and methods known to one skilled in the art. In step 1 of Scheme 4, the C-9 carbonyl, of formula |5, is converted to the corresponding oxime at the C-9 position by reacting the macrolide with hydroxylamine or preferably, a hydroxylamine salt such as a hydrochloride. Under presently preferred conditions, at least one molar equivalent, usually an excess, 5-10 equivalents, is usually employed in a weakly basic, tertiary amine (preferably pyridine) as a solvent; at a temperature range 20-80°C. A protic solvent, such as methanol, can also be used in conjunction with a base, such as barium carbonate, to provide a weakly basic solvent.
In step 2 of Scheme 4, the oxime of formula 6 may be reduced to the corresponding imine by treating with a metal halide such at TiCl3 in an acetate buffered solvent such as methanol or ethanol, methanol preferred. Reduction is also possible with divalent vanadium (prepared by Zn/Hg/HCI reduction of vanadyl sulphate) in a protic organic solvent such as methanol or ethanol, methanol preferred.
In step 3 of Scheme 4, the imine of formula 17 may be reduced to the corresponding amine, of formula Iji, by various methods familiar to those skilled in the art. A preferred method incorporates the use of boron reducing reagents such as sodium borohydride, generally used in excess, 2-10 equivalents, in protic solvents such as methanol or ethylene glycol, at a temperature range of -5-40°C, preferably 0-20°C.
The compounds of the present invention may have asymmetric carbon atoms and therefore exist in different enantiomeric and diastereomeric forms. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization. Enaπtiomers may be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. The use of all such isomers, including diastereomer mixtures and pure enantiomers, are considered to be part of the present invention.
The compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to mammals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The desired salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.
Those compounds of the present invention that are acidic in nature are capable of forming base salts with various cations. For compounds that are to be administered to mammals, fish or birds such salts must be pharmaceutically acceptable. Where a pharmaceutically acceptable salt is required, it may be desirable to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter to a pharmaceutically acceptable salt in a process analogous to that described above relating to the conversion of pharmaceutically unacceptable acid addition salts to pharmaceutically acceptable salts. Examples of base salts include the alkali metal or alkaline-earth metal salts and particularly the sodium, amine and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium, magnesium, various amine cations, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable bases with cations such as sodium, potassium, calcium, magnesium, various amine cations, etc., and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness In the same manner as before. In either case, stoichiσmetric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
The activity of the compounds of the present invention against bacterial and protozoa pathogens is demonstrated by the compound's ability to inhibit growtn of defined strains of human (Assay I) or animal (Assays II and 111) pathogens.
Assay I Assay I, descnbed below, employs conventional methodology and interpretation criteria and is designed to provide direction for chemical modifications that may lead to compounds that circumvent defined mechanisms of macrolide resistance. In Assay I, a panel of bacterial strains is assembled to include a variety of target pathogenic species, including representatives of macrolide resistance mechanisms that have been characterized. Use of this panel enables the chemical structure/activity relationship to be determined with respect to potency, spectrum of activity, and structural elements or modifications that may be necessary to obviate resistance mechanisms, Bacterial pathogens that comprise the screening panel are shown in the table below in many cases, both the macrolide-susceptible parent strain and the macrolide-resistant strain derived from it are available to provide a more accurate assessment of the compound's ability to circumvent the resistance mechanism. Strains that contain the gene with the designation of ormAAtrmBfermC are resistant to macrolides, lincosamides, and streptogramin B antibiotics due to modifications (methylation) of 23S rRNA molecules by an Erm methylase, thereby generally prevent the binding of all three structural classes. Two types of macrolide efflux have been described; msrA encodes a component of an efflux system in staphylococci that prevents the entry of macrolides and streptogramins while mβfA/E encodes a transmembrane protein that appears to efflux only macrolides. Inactivation of macrolide antibiotics can occur and can be mediated by either a phosphorylation of the 2'-hydroxyl (mph) or by cleavage of the macrocyclic lactone (esterase) The strains may be characterized using conventional polymerase chain reaction (PCR) technology and/or by sequencing the resistance determinant The use of PCR technology in this application is described in J. Sutciiffe et al., "Detection Of Erythromycin-Resistant Determinants By PCR". Antimicrobial Agents and Chemotherapy, 40(11), 2562-2566 (1996). The antibacterial assay is performed in microtiter trays and interpreted according to Performance Standards for Antimicrobial Disk Susceptibility Tests - Sixth Edition; Approved Standard, published by The National Committee for Clinical Laboratory Standards (NCCLS) guidelines; the minimum inhibitory concentration (MIC) is used to compare strains, acr AB or acr AB-like indicates that an intrinsia multidrug efflux pump exists in the strain. Compounds are initially dissolved in dimethylsulfoxide (DMSO) as 40 mg/ml stock solutions.
Figure imgf000049_0001
Figure imgf000050_0001
Assay II is utilized to test for activity against Pasteurella multocida and Assay III is utilized to test for activity against Pasteurella haemolytica.
Assay II This assay is based on the liquid dilution method in microtiter format. A single colony of
P. mult∞ida (strain 59A067) is inoculated into 5 ml of brain heart infusion (BHl) broth. The test compounds are prepared by solubilizing 1 mg of the compound in 125 μl of dimethylsulfoxide (DMSO). Dilutions of the test compound are prepared using uninoculated BHl broth. The concentrations of the test compound used range from 200 μg/ml to 0.098 μg/ml by two-fold serial dilutions. The P. multocida inoculated BHl is diluted with uninoculated BHl broth to make a 104 cell suspension per 200 μl. The BHl cell suspensions are mixed with respective serial dilutions of the test compound, and incubated at 37°C for 18 hours. The minimum inhibitory concentration (MIC) Is equal to the concentration of the compound exhibiting 100% inhibition of growth of P. multocida as determined by comparison with an uninoculated control. Assay III
This assay Is based on the agar dilution method using a Steers Replicator. Two to five colonies isolated from an agar plate are inoculated into BHl broth and incubated overnight at 37°C with shaking (200 rpm). The next morning, 300 μl of the fully grown P. haemolytica preculture is inoculated into 3 ml of fresh BHl broth and is incubated at 37 DC with shaking (200 rpm). The appropriate amounts of the test compounds are dissolved in ethanol and a series of two-fold serial dilutions are prepared. Two ml of the respective serial dilution is mixed with 18 ml of molten BHl agar and solidified. When the inoculated P. haemolytica culture reaches 0.5 McFarland standard density, about 5 μl of the P. haemolytica culture is inoculated onto BHl agar plates containing the various concentrations of the test compound using a Steers Replicator and incubated for 18 hours at 37 C. initial concentrations of the test compound range from 100-200 μg/ml. The MIC is equal to the concentration of the test compound exhibiting 100% inhibition of growth of P. haemolytica as determined by comparison with an uninoculated control.
The jn yj o activity of the compounds of formula (I) can be determined by conventional animal protection studies well known to those skilled in the art, usually carried out in mice. Mice are allotted to cages (10 per cage) upon their amval, and allowed to acclimate for a minimum of 48 hours before being used. Animals are inoculated with 0.5 ml of a 3 x 103 CFU/ml bacterial suspension (P. multocida strain 59A006) intrapentoneally. Each experiment has at least 3 non-medicated control groups including one infected with 0.1X challenge dose and two infected with 1X challenge dose; a 10X challenge data group may also be used. Generally, all mice in a given study can be challenged within 30-90 minutes, especially if a repeating syringe (such as a Cornwall® syringe) is used to administer the challenge. Thirty minutes after challenging has begun, the first compound treatment is given. It may be necessary for a second person to begin compound dosing if all of the animals have not been challenged at the end of 30 minutes. The routes of administration are subcutaneous or oral doses. Subcutaneous doses ere administered into the loose skin in the back of the neck whereas oral doses are given by means of a feeding needle In both cases, a volume of 02 ml is used per mouse Compounds are administered 30 minutes, 4 hours, and 24 hours after challenge. A control compound of known efficacy administered by the same route is included in each test. Animals are observed daily, and the number of survivors in each group is recorded. The P. multocida model monitoring continues for 96 hours (four days) post challenge.
The PDso is a calculated dose at which the compound tested protects 50% of a group of mice from mortality due to the bacterial infection which would be lethal in the absence of drug treatment.
The compounds of formula 1, 11, S and 0 and the pharmaceutically acceptable salts thereof (hereinafter "the active compounds"), may be adminstered through oral, parenteral, topical, or rectal routes in the treatment of bacterial and protozoa infections. In general, these compounds are most desirably administered in dosages ranging from about 0.2 mg per kg body weight per day (mg/kg/day) to about 200 mg/kg/day in single or divided doses (i.e., from 1 to 4 doses per day), although variations will necessanly occur depending upon the species, weight and condition of the subject being treated and the particular route of administration chosen. However, a dosage level that is in the range of about 4 mg/kg/day to about 50 mg/kg/day is most desirably employed, Vanations may nevertheless occur depending upon the species of mammal, fish or bird being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is earned out. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects, provided that such larger doses are first divided into several small doses for administration throughout the day. The active compounds may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by the routes previously indicated, and such administration may be carried out in single or multiple doses. More particulariy, the active compounds may be administered in a wide variety of different dosage forms, I.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules. lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the active compounds are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.
For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably com, potato or tapioca starch), alginic acid and certain complex silicatea, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia, Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials In this connection also Include lactose or milk sugar as well as high molecular weight polyethylene ølycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active compound may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
For parenteral administration, solutions of an active compound in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes, The oily solutions are suitable for intraarticular. intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques will known to those skilled in the art.
Additionally, It Is also possible to administer the active compounds of the present invention topically and this may be done by way of creams, jellies, gels, pastes, patches, ointments and the like, in accordance with standard pharmaceutical practice. For administration to animals other than humans, such as cattle or domestic animals, the active compounds may be administered in the feed of the animals or orally as a drench composition.
The active compounds may also be adminstered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phosphollplds, such as cholesterol, stearylamine or phosphatidylcholines.
The active compounds may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylam.de phenyl, polyhydroxyethylaspartamide-phenol. or polyethyleneoxide-potylysine substituted with palmitoylreβidueε. Furthermore, the active compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polygtycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactoπe, polyhydroxy butyric acid, polyorthoesters. polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
The following Examples further illustrate the method and intermediates of the present invention. It is to be understood that the present invention is not limited to the specific details of the Examples provided below.
The compounds of Examples 1 to θ have the general formula depicted with the R substituents indicated in the Tables below. The compounds were prepared as described in the Preparations described below. In the Tables, the yield and mass spectra ("Mass Spec") data apply to the final product
Tabie 1
Figure imgf000054_0001
Figure imgf000054_0002
Preparation 1
An amount of 0.095-4.96 g of the corresponding macrolide of formula 1 was dissolved in 1.9-50 mL of anhydrous pyridine. Hydroxylamine hydrochloride (7.5 equiv.) was added and the solution heated to 60" C and stirred for 24 hours. The reaction was worked up by decanting into
50 mL of a 1:1 mixture of methylene chloride and water. The pH of the reaction mixture was adjusted to 9-11 using 1N NaOH, the reaction mixture wasextracted 3 x 25 mL methylene chloride, and dried over Na2SOι. Filtration and concentration of filtrate yielded a light yellow solid product. The product was carried on to the next step without further purification.
Preparation for Example 1-1 (Table 1) 400 mg of the corresponding macrolide of formula _1_, where R1 is isopropyl and R2 is H, was dissolved in 8 mL of anhydrous pyridine. Hydroxylamine hydrochloride (0.2B5 g, 7.5 equiv.) was added and the solution heated to 60" C and stirred Tor 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted 3 x 25 mL methylene chloride, and dried over Na2S04. Filtration and concentration of filtrate yielded a light yellow solid product. The product (0.403 g) was carried on to the next step without further purification. Preparation for Example 1-2 (Table 1)
250 mg of the corresponding macrolide of formula 1_, where R1 is cyclopropyl and R2 is H, was dissolved in 5 mL of anhydrous pyridine. Hydroxylamine hydrochloride (0.178 g, 7.5 equiv.) was added and the solution heated to 60° C and stirred for 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1 NaOH, extracted 3 x 25 mL methylene chloride, and dried over Na2S04. Filtration and concentration of filtrate yielded a light yellow solid product. The product (0.252 g) was carried on to the next step without further purification.
Preparation for Example 1-3 (Table 1) 250 mg of the corresponding macrolide of formula 1_, where R1 is see-butyl and R2 is H, was dissolved in 5 mL of anhydrous pyridine. Hydroxylamine hydrochloride (0.175 g, 7.5 equiv.) was added and the solution heated to 60° C and stirred for 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted 3 x 25 mL methylene chloride, and dried over NaaSO«, Filtration and concentration of filtrate yielded a light yellow solid product. The product (0.246 g) was carried on to the next step without further purification.
Preparation for Example 1-4 (Table 1) 250 mg of the corresponding macrolide of formula 1, where R1 is cyclobutyl and R2 is H, was dissolved in 5 mL of anhydrous pyridine. Hydroxylamine hydrochloride (0.175 g, 7.5 equiv.) was added and the solution heated to 60" C and stirred for 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1 N NaOH. extracted 3 x 25 mL methylene chloride, and dried over Na2S0 . Filtration and concentration of filtrate yielded a light yellow solid product. The product (0.249 g) was carried on to the next step without further purification.
Preparation for Example 1-5 (Table 1) 100 mg of the corresponding macrolide of formula 1, where R1 is cyclopentyl and R2 is H, was dissolved In 2 mL of anhydrous pyridine. Hydroxylamine hydrochlortde (0.070 g, 7.5 equiv.) was added and the solution heated to 60° C and stirred for 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9-11 using 1N NaOH, extracted 3 x 25 mL methylene chloride, and dried over Na2SOΛ. Filtration and concentration of filtrate yielded a light yellow solid product. The product (0.094 g) was earned on to the next step without further purification.
Preparation for Example 1-6 (Table 1) 95 mg of the corresponding macrolide of formula 1_, where R1 is methylthioethyl and R2 is H, was dissolved in 1.9 mL of anhydrous pyridine. Hydroxylamine hydrochloride (0.065 g, 7.5 equiv.) was added and the solution heated to 60° C and stirred for 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted 3 x 25 mL methylene chloride, and dried over Na2S04. Filtration and concentration of filtrate yielded a light yellow solid product. The product (0.091 g) was carried on to the next step without further purification.
Preparation for Example 1-7 (Table 1) 98 mg of the corresponding macrolide of formula Λ_, where R1 is cyclopropyl and R2 is
OH, was dissolved in 2.0 mL of anhydrous pyridine. Hydroxylamine hydrochloride (0.068 g, 7.5 equiv.) was added and the solution heated to 60° C and stirred for 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted 3 x 25 mL methylene chloride, and dried over Na2S04. Filtration and concentration of filtrate yielded a light yellow solid product. The product (0.100 g) was carried on to the next step without further purification.
Preparation for Example 1-8 (Table 1) 4.9(3 g of the corresponding macrolide of formula 1_, where R1 Is cyclobutyl and R2 Is OH. was dissolved in 50.0 mL of anhydrous pyridine. Hydroxylamine hydrochloride (3.4 g. 7.5 equjv.) was added and the solution heated to 60° C and stirred for 24 hours. The reaction was worked up by decanting into 50 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted 3 x 25 mL methylene chloride, and dried over Na S j. Filtration and concentration of filtrate yielded a light yellow solid product. The product (4.24 g) was carried on to the next step without further purification.
Table 2
Figure imgf000057_0001
Figure imgf000057_0002
Preparation 2
An amount of 60-500 mg of the corresponding oxime of formula 2 was dissolved in 1-7 mL of acetone. A 0.1 M aqueous solution of Na2HCOs (2 equiv.) was added and the resulting mixture was cooled to 0-5° C. A 0.1 M solution of pa/a-tolueneεulfonyl chloride in acetone, cooled to 0-5° C, was added and the mixture stirred overnight The reaction was worked up by decanting into 25 mL of a 1:1 mixture of methylene chloride and water. The pH of the reaction mixture was adjusted to 9-10 using 1N NaOH, the reaction mixture was extracted with 3 x 20 mL methylene chloride, and dried over Na2S04. Filtration, concentration of filtrate yielded a solid product. The product was carried on to the next step without further purification. Preparation for Example 2-1 (Table 2)
415 mg of the corresponding oxime of formula 2, where R1 is isopropyl and R2 is H, was dissolved in 7 L of acetone. A 0.1 M aqueous solution of Na2HC03 (0.193 g in 2.0 L water) was added and the resulting mixture was cooled to 0° C. A solution of para- toluenesulfonyl chloride (0.220 g) in acetone (2.0 mL), cooled to 0P C. was added and the mixture stirred ovemight, The reaction was worked up by decanting into 25 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1 N NaOH, extracted with 3 x 20 mL methylene chloride, and dried over Na2S04. Filtration, concentration of filtrate yielded a solid product. The product (0.329 g) was carried on to the next step without further purification. Preparation for Example 2-2 (Table 2)
200 mg of the corresponding oxime of formula 2, where R1 is isopropyl and R2 is H, was dissolved in 2 mL of acetone. A 0.1 M aqueous solution of Na2HC03 (0.093 g in 1.0 mL water) was added and the resulting mixture was cooled to 0β C. A solution of para- toluenesulfoπyl chloride (0.10S g) in acetone (1.0 mL), cooled to 0° C, was added and the mixture stirred overnight. The reaction was worked up by decanting into 25 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted with 3 x 20 mL methylene chloride, and dried over Na2S04. Filtration, concentration or filtrate yielded a solid product. The product (0.177 g) was carried on to the next step without further purification. Preparation for Example 2-3 (Table 2)
420 mg of the corresponding oxime of formula 2, where R1 is sec-butyl and R2 is H, was dissolved in 7 mL of acetone. A 0.1 M aqueous solution of a2HCθ3 (0.192 g in 2.0 mL water) was added and the resulting mixture wee cooled to 0° C. A solution of para- toluenesulfonyl chloride (0.220 g) in acetone (2.2 mL), cooled to 0° C, was added and the mixture stirred overnight. The reaction was worked up by decanting into 25 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted with 3 x 20 mL methylene chloride, and dried over Na2S04. Filtration, concentration of filtrate yielded a solid product The product (0.348 g) was carried on to the next step without further purification. Preparation for Example 2-4 (Table 2)
500 mg of the corresponding oxime of formula 2, where ' Is cycloburyl and Ra Is H, was dissolved in 5 mL of acetone. A 0.1 M aqueous solution of Na2HC03 (0,229 g in 2.0 mL water) was added and the resulting mixture was cooled to 0° C. A solution of para- toluenesulfonyl chloride (0.260 g) in acetone (2.0 mL), cooled to 0° C, was added and the mixture stirred overnight, The reaction was worked up by decanting into 25 mL of a 1 :1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1 N NaOH, extracted with 3 x 20 mL methylene chloride, and dried over Na2S04. Filtration, concentration of filtrate yielded a solid product The product (0.485 g) was carried on to the next step without further purification.
Preparation for Example 2-5 (Table 2) 84 mg of the corresponding oxime of formula 2, where R1 Is cyclopentyl and R2 Is H, was dissolved in 1 mL of acetone. A 0.1 M aqueous solution of Na2HC03 (0.038 g in 0.5 mL water) was added and the resulting mixture was cooled to 0° C. A solution of para- toluenesulfonyl chloride (0.043 g) in acetone (0.5mL), cooled to 0° C, was added and the mixture stirred ovemight The reaction was worked up by decanting into 25 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1 N NaOH, extracted with 3 x 20 mL methylene chloride, and dried over Na2S04. Filtration, concentration of filtrate yielded a solid product. The product (0.042 g) was carried on to the next step without further purification.
Preparation for Example 2-8 (Table 2) 85 mg of the correspondino oxime of formula 2, where R1 is methylthioethyl and R2 is
H, was dissolved in 1 mL of acetone. A 0.1 M aqueous solution of Na2HC03 (0.038 g in 0.5 mL water) was added and the resulting mixture was cooled to 0° C. A solution of para- toluenesulfonyl chloride (0.043 g) in acetone (0.5mL), cooled to 0° C, was added and the mixture stirred overnight. The reaction was worked up by decanting into 25 mL of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted with 3 x 20 mL methylene chloride, and dried over Na2S04. Filtration, concentration of filtrate yielded a solid product. The product (0.024 g) was carried on to the next step without further purification.
Preparation for Example 2-7 (Table 2) 60 mg of the corresponding oxime of formula 2, where R1 is cyclopropyl and R2 is OH, was dissolved in 1 mL of acetone. A 0.1 M aqueous solution of Na2HC03 (0.027 g in 0.5 mL water) was added and the resulting mixture was cooled to 0° C. A solution of para- toluenesulfonyl chloride (0.031 g) in acetone (0.5mL). cooled to 0° C, was added and the mixture stirred overnight The reaction was worked up by decanting into 25 L of a 1:1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted with 3 x 20 mL methylene chloride, and dried over Na2S04. Filtration, concentration of filtrate yielded a solid product. The product (0.058 g) was carried on to the next step without further purification. Preparation for Example 2-8 (Table 2)
500 mg of the corresponding oxime of formula 2, where R1 is cyclobutyl and R2 is OH, was dissolved in 5 mL of acetone. A 0,1 M aqueous solution of Na2HC03 (0.224 g in 2.5 mL water) was added and the resulting mixture was cooled to 0° C. A solution of para- toluenesulfonyl chloride (0.255 g) in acetone (2.5mL), cooled to 0° C, was added and the mixture stirred ovemight. The reaction was worked up by decanting into 25 mL of a 1: 1 mixture of methylene chloride and water. The pH was adjusted to 9 using 1N NaOH, extracted with 3 x 20 mL methylene chloride, and dried over Na2S04. Filtration, concentration of filtrate yielded a solid product. The product (0.485 g) was carried on to the next step without further purification. Table 3
Figure imgf000060_0001
Figure imgf000060_0002
Preparation 3
An amount of 42-165 mg of the corresponding imidate of formula 3 was dissolved in glacial acetic acid. Platinum oxide catalyst (50 mole %) was added, the reaction flushed with nitrogen, placed under 50 psi hydrogen and shaken at room temperature for 24 hours. Additional platinum oxide catalyst (50 mole %) was added, the reaction flushed with nitrogen, placed under 50 psi hydrogen and shaken at room temperature for additional 24-48 hours. The reaction was worked up by Alteration through Celite™. 25 mL of water was added and the pH of the reaction mixture adjusted to 9-10 using 1N NaOH, the reaction mixture was extracted 3 x 25 mL methylene chloride, and dried over Na2S04. Filteration and concentration of the filtrate yielded a solid product mixture containing azalide of formula 4 and lactam of formula 5. Isolation was accomplished by preparative HPLC.
Preparation 4 An amount of 11-250 mg of the corresponding imidate of formula 3 was dissolved in THF and ethylene glycol then cooled to 0-5° C. NaBH4 (5-10 equiv.) was added and the reaction stirred tor 4 hours at 0-56 C and then warmed to room temperature. The reaction was worked up by decanting into 10 mL of a 1:1 mixture of methylene chloride and water. The aqueous was re-extracted 3 x 5 mL methylene chloride. The organic layers were combined and dried over Na2S04. Filteration and concentration yielded a solid product
Preparation for Example 3-1 (Table 3) 150 mg of the corresponding imidate of formula 3, where R1 is isopropyl and R2 is H, was dissolved in 3.75 mL tetrahydrofuran and 7.5 mL ethylene glycol and then cooled to 0-5° C. NaθH4 (0.039 g) was added and the reaction stirred for 6 hours at 0-5° C and then warmed to room temperature. The reaction was worked up by decanting into 10 mL of a 1:1 mixture of methylene chloride and water. The aqueous was re-extracted 3 x 5 mL methylene chloride. The organic layers were combined and dried over NazS04. Filteration and concentration yielded a solid product (0.1 9 g).
Preparation for Example 3-2 (Table 3) 165 mg of the corresponding imidate of formula 3, where R1 is cyclopropyl and R2 is H, was dissolved In glacial acetic acid (20 mL) . Platinum oxide catalyst (0.026 g, 50 mole %) was added, the reaction flushed with nitrogen, placed under 50 psi hydrogen and shaken at room temperature for 24 hours. Additional platinum oxide catalyst (50 mole %) was added, the reaction flushed with nitrogen, placed under 50 psi hydrogen and shaken at room temperature for additional 24 hours. Reaction was worked up by filteration through Celite™. 25 mL of water was added and the pH adjusted to 9 using 1N NaOH, extracted 3 x 25 mL methylene chloride, and dried over Na2S04. Filteration and concentration of the filtrate yielded a solid product mixture containing azalide of formula 4 and lactam of formula 5. Isolation was accomplished by preparative HPLC (0.019 g).
Preparation for -Example 3-3 (Table 3) 11 mg of the corresponding imidate of formula 3, where R1 sec-butyl and R2 is H, was dissolved in 0.275 mL tetrahydrofuran and 0.55 mL ethylene glycol and then cooled to 0-5° C. NaBH4 (0.003 g) was added and the reaction stirred for 6 hours at 0-5° C and then warmed to room temperature. The reaction was worked up by decanting into 10 mL of a 1:1 mixture of methylene chloride and water. The aqueous was re-extracted 3 x 5 mL methylene chloride. The organic layers were combined and dried over Na2S04. Filteration and concentration yielded a solid product (0.005 g).
Preparation for Example 3-4 (Table 3) 250 mg of the corresponding imidate of formula 3, where R1 cyclobutyl and R2 is H, was dissolved in 3.83 mL tetrahydrofuran and 5.0 mL ethylene glycol and then cooled to 0-5p C. NaBH4 (0.191 g) was added and the reaction stirred for 6 hours at 0-5° C and then warmed to room temperature. The reaction was worked up by decanting into 10 mL of a 1:1 mixture of methylene chloride and water. The aqueous was re-extracted 3 x 5 L methylene chloride. The organic layers were combined and dried over Na2S04. Filteration and concentration yielded a solid product (0.201 g).
Preparation for -Example 3-5 (Table 3) 42 mg of the corresponding imidate of formula 3, where R1 is cyclopentyl and Ra is H, was diβsolved in glacial acetic acid (10 mL) . Platinum oxide catalyst (0.006 g, 60 mole %) was added, the reaction flushed with nitrogen, placed under 50 psi hydrogen and shaken at room temperature for 24 hours. Additional platinum oxide catalyst (50 mole %) was added, the reaction flushed with nitrogen, placed under 50 psi hydrogen and shaken at room temperature for additional 24 hours. Reaction was worked up by filteration through Celite™. 25 mL of water was added and the pH adjusted to 9 using 1N NaOH, extracted 3 x 25 mL methylene chloride, and dried over Na2SQ4. Filteration and concentration of the filtrate yielded a solid product mixture containing azalide of formula 4 and lactam of formula 5. Isolation was accomplished by preparative HPLC ( 0.037 g).
Preparation for Example 3-6 (Table 3) 60 g of the corresponding imidate of formula 3, where R1 cyclopropyl and R2 is OH, was dissolved in 0.6 mL tetrahydrofuran and 1.8 mL ethylene glycol and then cooled to 0-5° C. NaBH4 (0.046 g) was added and the reaction stirred for 6 hours at 0-5" C and then warmed to room temperature. The reaction was worked up by decanting into 10 L of a 1:1 mixture of methylene chloride and water. The aqueous was re-extracted 3 x 5 mL methylene chloride. The organic layers were combined and dried over Na2S04. Filteration and concentration yielded a solid product (0.055 g). Preparation for Example 3-7 (Table 3)
250 mg of the corresponding imidate of formula 3, where R1 cyclobutyl and R2 is OH, was dissolved in 3.75 mL tetrahydrofuran and 5,0 mL ethylene glycol and then cooled to 0-5° C. NaBH4 (0.187 g) was added and the reaction stirred for 6 hours at 0-5° C and then warmed to room temperature. The reaction was worked up by decanting into 10 mL of a 1:1 mixture of methylene chloride and water. The aqueous was re-extracted 3 x 5 mL methylene chloride. The organic layers were combined and dried over Na2S04. Filteration and concentration yielded a solid product (0.226 g).
T e nmr data for compounds included within those of formula 5 is shown in Tables 3A and 38 below. Table 3A
Figure imgf000063_0001
Figure imgf000063_0002
Figure imgf000064_0001
Figure imgf000065_0002
Table 3B
Figure imgf000065_0003
Figure imgf000066_0001
-Θ5-
Table 4
Figure imgf000067_0001
Figure imgf000067_0002
Preparation 5
The corresponding azalide or formula 5 was dissolved in chloroform. 37% formaldehyde (3.0 equiv.) and formic acid (3.0 equiv.) was added and the solution stirred at 45-
50° C for 12-24 hours. The reaction mixture was then concentrated under vacuum. The residue was then dissolved in 1-2 mL of methylene chloride. 2-5 mL of a saturated NaHC03 aqueous solution was then added. The layers were separated and the aqueous re-extracted with an equal volume of methylene chloride. The organics were combined and dried over Na2S04. Filtered, concentrated, and isolated a solid. -ββ-
Preparation for {Example 4-1 (Table 4)
25 mg of the corresponding azalide of formula 5, where R1 is isopropyl and Rz is H, was dissolved in 1.0 mL chloroform. 37% formaldehyde (7.5 microliter, 3.0 equiv.) and formic acid (10.5 microliter, 3.0 equiv.) was added and the solution stirred at 45-50° C for 24 hours. The reaction mixture was then concentrated under vacuum. The residue was then dissolved in 2 mL of methylene chloride. 5.0 mL of a saturated NaHC03 aqueous solution was then added. The layers were separated and the aqueous re-extracted with an equal volume of methylene chloride. The organics were combined and dried over Na-jSO.,. Filtered, concentrated, and isolated a solid (0.023 g).
Preparation for Example 4-2 (Table 4) 20 mg of the corresponding azalide of formula 5, where R1 is cyclopropyl and R2 is OH, was dissolved in 2.0 mL chloroform. 37% formaldehyde (6 microliter, 3.0 equiv.) and formic acid (8.5 microliter, 3.0 equiv.) was added and the solution stirred at 45-50° C for 12 hours. The reaction mixture was then concentrated under vacuum. The residue was then dissolved in 2 mL of methylene chloride. 5.0 mL of a saturated NaHCQ3 aqueous solution was then added. The layers were separated and the aqueous re-extracted with an equal volume of methylene chloride. The organics were combined and dried over Na2S04. Filtered, concentrated, and isolated a solid (0.019 g).
Table 5
Figure imgf000068_0001
Figure imgf000068_0002
Figure imgf000069_0002
Preparation 6 The corresponding oxime of formula 2 is dissolved in ethanol. Lithium hydroxide monohydrate (2 equivalents) is added and the reaction mixture stirred ovemight at room temperature. The reaction is concentrated under vacuum and partitioned between brine and ethyl acetate, the pH of the reaction mixture is adjusted to 9-10, the reaction mixture is extracted with ethyl acetate, and dried over Na2S04. A 4:1 ratio of Z:E isomers is produced. Isolation of isomers is accomplished by either silica chromatography or crystallization from nitromethane.
Table 6
Figure imgf000069_0001
Figure imgf000069_0003
Figure imgf000070_0002
Preparation 7 The corresponding oxime of formula 2a is dissolved in acetone. A 0.1 M aqueous solution of NagHCOa (2 equiv.) is added and the resulting mixture is cooled to 0-5° C. A 0.1 M solution of para-toluenesulfonyl chloride in acetone is added and the mixture stirred overnight. The reaction is worked up by decanting into 25 mL of a 1:1 mixture of methylene chloride and water. The pH of the reaction mixture is adjusted to 9-10 using 1N NaOH, the reaction mixture is extracted with 3 x 20 mL methylene chloride, and dried over Na2S04. Filtration and concentration of filtrate yields a solid product. The product is carried on to the next step without further purification. Table 7
Figure imgf000070_0001
Figure imgf000070_0003
Figure imgf000071_0002
Preparation 8
The corresponding imidate of formula 3a is dissolved in glacial acetic acid. Platinum oxide catalyst (50 mole %) is added, the reaction is flushed with nitrogen, placed under 50 psi hydrogen and shaken at room temperature for 24 hours. Additional platinum oxide catalyst (50 mole %) is added, the reaction is flushed with nitrogen, placed under 50 psi hydrogen and shaken at room temperature for additional 24-48 hours. The reaction is worked up by filtration through Celite™. A volume of 25 mL of water is added and the pH of the reaction mixture is adjusted to 9-10 using 1N NaOH, the reaction mixture is extracted 3 x 25 mL methylene chloride, and dried over Na2S04. Filtration and concentration yields a solid product Isolation is accomplished by HPLC.
Preparation 9 The corresponding imidate of formula 3a is dissolved in 0.5 mL MeOH and cooled to 0-5° C. NaBH4 (10 equiv.) is added and the reaction stirred for 4 hours at 0-5° C, warmed to room temperature, and stirred ovemight. The reaction is worked up by decanting into 10 mL of a 1:1 mixture of methylene chloride and water, the pH of the reaction mixture adjusted to β-g using i N NaOH, extracted 3 x 5 mL methylene chloride, and dried over Na-jSO,. Filtration and concentration yields a solid product Purification is accomplished by HPLC.
Table 8
Figure imgf000071_0001
Figure imgf000072_0001
Preparation 10 The corresponding azalide of formula 5§ is dissolved in chloroform. 37% formaldehyde (1.0 equiv.) and formic acid (1.0 equiv.) is added and the solution stirred at 45-50° C for 48-72 hours. The reaction mixture is then decanted into a 1:1 mixture of chloroform and water, the pH of the reaction mixture is adjusted to 9-10 using 1N NaOH, the reaction mixture is extracted with chloroform, and dried over Na2S04. Filtration and concentration yields a solid product. Isolation of product is accomplished by either silica chromatography or HPLC.
Preparation 11 An amount of 100-200 mg of the corresponding azalide Is dissolved in a solution of
MeOH (5-1 OmL) and acetyl chloride (2.6 equivalents). The resulting mixutre is stirred ovemight at room temperature, concentrated under vacuum, and then taken up in a small amount of MeOH (1mL). The mixture is then heated, combined with hot cyclohexaπe (10mL), and cooled to room temperature. The product is isolated by filtration.

Claims

CLMMS
A compound of the formula
Figure imgf000073_0001
or a pharmaceutically acceptable salt thereof, wherein:
Y is H, CrC.,0 alkyl, C2-C10 alkenyl, C C10 alkynyl, -(CH2)mCβ-C10aryl, -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano. nitro. trifluoromethyl, azido, -C(0)R21, -OC(0)R21, - NR21C(0)R22, -C(0)NR21R22, -NR^R22. hydroxy, C,-C, alkyl, C,-C6 alkoxy, Cβ-C10 aryl. and 5- 10 membered heteroaryl; R1 is an alpha-branched CyC8 alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C3-C„ cycloalkylalkyi group wherein the alkyl group is an alpha-branched C2-C3 alkyl group; a C3-C, cycloalkyi or C5-Cβ cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more CrC4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more CrC4 alkyl groups or halo atoms; or R1 is phenyl which may be optionally substituted with at least one substituent selected from C,-C alkyl. C,-C4 alkoxy and CrC4 alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl. and cyano; or R1 may be with a formula (a) as shown below:
Figure imgf000074_0001
wherein X is O, S or -CH2-, a, b, c, and d are each Independently an integer ranging from 0 to 2 and a + b + c + d < 5; or R1 is CH2R2\ wherein R24 is H, C,-Cβalkyl, C2-Cβalkenyl, C2-Cβalkynyl, alkoxyalkyl or alkylthioalkyl containing from 1 to 6 carbon atoms in each alkyl or alkoxy group wherein any of said alkyl, alkoxy, alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a C3-C8cycloa|kyl or C.j-CBeycloalkenyl either or which may be optionally substituted by methyl or one or more C,-C4alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated or fully or partially unsaturated and which may optionally be substituted by one or more c.-c alkyl groups or halo atoms; or a group of the formula SR23 wherein Rz3 is Cr
Cβalkyl, C2-Cβalkenyl. C2-C„alkynyl. C,-Cβcycloalkyl, Cs-Ccycloalkenyl. phenyl or substituted phenyl wherein the substituent is C1-C4alkyl, CrC4alkoxy or halo, or a 3 to 6 membered oxygen or sulphur-containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C,-C4alkyl groups or halo atoms;
R2 is H or OH; R3 is H, OH, or 0CH3;
R4 is H, -C(0)Rβ, -C(0)OR8, -C(0)NRβ R10 or a hydroxy protecting group; R5 is -SR8, -(CH2)nC(0)R8 wherein n is 0 or 1, C,-C10 alkyl, C2-C10 alkenyl, C2- Co alkynyl. -(CH2)m(C,-C,0 aryl). or -(CHa)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing Rs groups are optionally substituted by 1 to 3 R16 groups; each Rβ and R7 is independently H, hydroxy, CrCβ alkoxy, C-Cg alkyl, C2-C6 alkenyl, C Cβ alkynyl, -(CH2)m(Cβ-C,0 aryl), or -(CH^ δ-IO membered heteroaryl), wherein m is an integer ranging from 0 to 4; each R8 is independently H, C,-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, -(CH2)qCR11 12(CH2)rNR13R14 wherein q and r are each independently an integer ranging from 0 to 3 except q and r are not both 0, -(CH2)m(C6-C10 aryl), or -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R8 groups, except H, are optionally substituted by 1 to 3 R1β groups; or where R8 is as -CH2NRBR15, R,s and R* may be taken together to form a 4-10 membered monocy ic or poiycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S and -N(R8)-, in addition to the nitrogen to which R15 and R8 are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R1β groups; each R9 and R10 is independently H or C,-Cβ alkyl; each 11, R12, R13 and R is independently selected from H, CrC10 alkyl. -(CH2)m(C6-
C10 aryl), and -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R11, R12. R13 and R14 groups, except H, are optionally substituted by 1 to 3 R1B groups; or R11 and R13 are taken together to form -(CH2)p- wherein p is an integer ranging from 0 to 3 εuch that a 4-7 membered saturated ring is formed that optionally includes 1 or 2 carbon-carbon double or triple bonds; or R13 and R14 are taken together to form a 4-10 membered monocyclic or poiycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally Include 1 or 2 heteroatoms selected from O, S and -N(R8)-, in addition to the nitrogen to which R13 and R14 are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R16 groups;
R1S is H, 0,-0,0 alkyl, c2-c10 alkenyl, or C2-c10 alkynyl, wherein the foregoing RlS groups are optionally substituted by 1 to 3 substituents independently selected from halo and - ORβ; each R1β is independently selected from halo, cyano, nitro, trifluoromethyl, azido, - C(0)R17, -C(0)0R17, -C(0)OR17, -OC(0)OR17, -NRβC(0)R7, -C(0)NR6R7, -NR6R7, hydroxy, C-|-Ce alkyl, C--C6 alkoxy, -(CH2)m(Ce-C10 aryl), and -(CH2)m(S-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein said aryl and heteroaryl subsituents are optionally substituted by 1 or 2 substituents independently selected from halo, cyano, nitro, trifluoromethyl. azido, -C(0)R17, -C(0)OR17, -C(0)OR1V, -OC(0)OR17, -NRBC(0)R7, - C(0)NR6R7, -NR6R7, hydroxy, C,-C6 alkyl, and C,-Ce alkoxy; each R17 is independently selected from H, C,-C10 alkyl. C2-C,0 alkenyl, C3-C10 alkynyl, -(CH2)m(C8-C10 aryl), and -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, provided that R8 is not H where R'9 is -CH2S(0)„R8; R1β is OH;
R19 is -Co alkyl, C C10 alkenyl, C2-C10 alkynyl, cyano, -CH2S(0)nRB wherein n is an integer ranging from 0 to 2, -CH2OR8, -CH2N(ORe)R8, -CH2NR8R15, -(CH2)m(C6-C10 aryl), or - (CHj δ-IO membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R19 groups are optionally substituted by 1 to 3 R16 groups; or R18 and R1B are taken together to form an oxazolyl ring as shown below
Figure imgf000076_0001
and; each R21 and R22 is independently H, hydroxy, C-Cβ alkoxy, C,-C3 alkyl, C2-Cβ alkenyl, (CH2)m(C6-C10) aryl, (CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, or C2-C10 alkylyl.
2. A compound of the formula
Figure imgf000076_0002
or a pharmaceutically acceptable salt thereof, wherein: Y is H, C-C alkyl, CrCi0 alkenyl, C2-C10 alkynyl, -(CH2)mC6-C10aryl, -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl. alkenyl, aryl, heteroaryl and alkynyl groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(0)R21, -OC(0)R21, - N ^C JR", -C(0)NR81Rw, -NR4,RM, hydroxy, C,-C6 alkyl, CrC6 alkoxy, Cε-C10 aryl, and 5- 10 membered heteroaryl;
R1 is an alpha-branched C3-Cβ alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C6-Cβ cycloalkylalkyi group wherein the alkyl group is an alpha-branched C2-Cβ alkyl group; a C3-C„ cycloalkyi or C5-C„ cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more CrC4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C-C4 alkyl groups or halo atoms; or R1 Is phenyl which may be optionally substituted with at least one substituent selected from CrC4 alkyl, C,-C alkoxy and C,-C4 alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano; or R1 may be with a formula (a) as shown below:
Figure imgf000077_0001
wherein X is 0. S or -CH,-, a, b, c, and d are each independently 0-2 and a + b + c + d < 5; or R1 is CH2R24, wherein R24 is H, CrC8alky|, C2-Cβalkenyl, C2-C8alkynyl, alkoxyalkyl or alkylthioalkyl containing from 1 to 6 carbon atoms in each alkyl or alkoxy group wherein any of said alkyl, alkoxy, alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a C3-Cβcyc alkyl or C5-C„cyc|oalkenyl either or which may be optionally substituted by methyl or one or more C1-C4alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated or fully or partially unsaturated and which may optionally be substituted by one or more C C4a!kyl groups or halo atoms; or a group of the formula SR23 wherein R23 is C,- Caalkyl. Ca-Cβa|kenyl. C -Ctalkynyl, C3-Cacycloalkyl, C5-C,cycloalkenyl, phenyl or substituted phenyl wherein the substituent is C1-C4alkyl, CrC4alkoxy or halo, or a 3 to 6 membered oxygen or sulphur-containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C,-c4aikyi groups or halo atoms; R2 is H or OH;
R3 is H, OH, or OCH3;
R4 is H, -C(0)RB, -C(0)ORβ, -C(0)NR'R10 or a hydroxy protecting group; each Rβ and R10 is Independently H or C|-C6 alkyl;
R18 is OH; R19 is H and; each R21 and R22 is independently H, hydroxy, C,-CB alkoxy, CrCβ alkyl, C2-C6 alkenyl, (CH2)m(Cβ-C,0) aryl, (CH2)m(5-10 membered heteroaryl), wherein m is an integer de¬
ranging from 0 to 4, or C2-C10 alkylyl.
3. The compound of formula I of claim 1
20 , wherein R is
Figure imgf000078_0001
1 is isopropyl, R2 Is H and R19 Is OH; R1 is isopropyl, R2 is OH and R19 is OH; R1 is cyclopropyl. Rzis H and R19 is OH; R1 is cyclopropyl, R2 is OH and R1β is OH; R1 is sec-butyl, R2 is H and R1' is OH; R1 is sec-butyl, R2 is OH and R19 is OH; R1 is cyclobutyl, R2 is H and R1β is OH; R1 is cyclobutyl, R2 is OH and R18 is OH; R1 is cyclopentyl. R2is H and R 9 is OH; R1 is cyclopentyl, Ra is OH and R1B is OH; R1 is methylthioethyl, R2 is H and R19 is OH; R1 is methylthioethyl, R2 is OH and R Dis OH; R1 is 3-furyl, R2 is H and R1β is OH; or R1 is 3-furyl, R2 is OH and R19 is OH. 4. The compound of formula II of claim 2 wherein R20 is
Figure imgf000078_0002
R1 is isopropyl, R2 is H and R 9 is OH; R1 is isopropyl, R2 is OH and R1β is OH; R1 is cyclopropyl, R2 is H and R18is OH; R1 is cyclopropyl, R2 is OH and R1B is OH; R1 is sec-butyl, R2 is H and R19 is OH; R1 is sec-butyl, Rz is OH and R19 is OH; R1 is cyclobutyl, R2 is H and R19 is OH; R1 is cyclobutyl, R2 is OH and R19 is OH; R1 is cyclopentyl, R2 is H and R19 is OH; R1 is cyclopentyl, R2 is OH and R 9 is OH; R1 is methylthioethyl, R2 is H and R19 is OH; R1 is methylthioethyl, R2 is OH and R1B is OH; R1 is 3-furyl. R2 is H and R1β is OH; or R1 is 3-furyl, R is OH and R19 is OH. 5. A compound of the formula
Figure imgf000079_0001
or a pharmaceutically acceptable salt thereof, wherein:
R1 is an alpha-branched C,-C„ alkyl, alkenyl, alkynyl. alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C5-Cβ cycloalkylalkyi group wherein the alkyl group is an alpha-branched C2-C3 alkyl group; a C3-C„ cycloalkyi or Cs-Cs cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more 0,-04 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more CrC4 alkyl groups or halo atoms; or R1 is phenyl which may be optionally substituted with at least one substituent selected from C,-C4 alkyl, C,-Ct alkoxy and C,-C4 alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano; or R1 may be with a formula (a) as shown below:
wherein X is O, S or -CH2-, a, b, c, and d are each independently 0-2 and a + b + c + d < 5; or R1 is CHzR24, wherein R is H, C1-C8alkyl, C2-C8alkenyl, C2-Cβalkynyl, alkoxyalkyl or alkylthioalkyl containing from 1 to 6 carbon atoms In each alkyl or alkoxy group wherein any of said alkyl, alkoxy, alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a C3-C8cycloalkyl or C5-C8cycloalkenyl either or which may be optionally substituted by methyl or one or more CrC4alkyi groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated or fully or partially unsaturated and which may optionally be substituted by one or more C..-C4alkyl groups or halo atoms; or a group of the formula SR23 wherein R23 is C,- C8alkyl, C2-C8alkenyl, C2-C„alkynyl, C3-CBcycloalkyl, C3-C„cycloalkenyl, phenyl or substituted phenyl wherein the substituent is CrC4alkyl, CrC4alkoxy or halo, or a 3 to 6 membered oxygen or sulphur-containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C1-C4alkyl groups or halo atoms; and
R2 is H or OH.
A compound of the formula
Figure imgf000081_0001
or a pharmaceutically acceptable salt thereof, wherein;
R1 Is an alpha-branched C3-Ca alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C5-C„ cycloalkylalkyi group wherein the alkyl group is an alpha-branched C2-C3 alkyl group; a C,-CB cycloalkyi or C5-C8 cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more C,-C4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C,-C4 alkyl groups or halo atoms; or R1 is phenyl which may be optionally substituted with at least one substituent selected from Crc4 alkyl, CrC4 alkoxy and CrC4 alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano; or R, may be with a formula (a) as shown below:
Figure imgf000081_0002
wherein X is O, S or -CH2~, a, b, c, and d are each independently 0-2 and a + b + c + d ^5; or R1 is CH2R2J, wherein Ru is H, d-Caalkyl, Cj-Cgalkenyl, Cj-Cgalkynyl, alkoxyalkyl or alkylthioalkyl containing from 1 to 6 carbon atoms in each alkyl or alkoxy group wherein any of said alkyl, alkoxy, alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a C3-C8cycloalkyl or C3-
Cacycloalkenyl either or which may be optionally substituted by methyl or one or more C,- C4alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated or fully or partially unsaturated and which may optionally be substituted by one or more C,-C4alkyl groups or halo atoms; or a group of the formula SR23 wherein R23 Is
Figure imgf000082_0001
C2-CBaikenyi, CrC8aikynyi, C3-C8cycioalkyl,
C5-C8cycloalkenyl, phenyl or substituted phenyl wherein the substituent is C^C^alkyl, C-,- C4alkoχy or halo, or a 3 to 6 membered oxygen or sulphur-containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C1-C4alkyl groups or halo atoms;and R2 is H or OH.
7. A pharmaceutical composition for the treatment of a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises a therapeutically effective amount of a compound of claims 1, 2, 3, 4, 5, or 6 and a pharmaceutically acceptable carrier. 8. A method of treating a bacterial infection or a protozoa infection in a mammal. fish, or bird which comprises administering to said mammal, fish or bird a therapeutically effective amount of a compound of claims 1, 2, 3, , 5 or 6. g. A process for preparing a compound of the formula
Figure imgf000082_0002
wherein R1 and Ra are as defined in claim 1, which comprises treating a compound of the formula
Figure imgf000083_0001
wherein R1 and R2 are as defined in claim 1, with a reducing agent.
10. The process of claim 9 wherein the reducing agent is NaBH4 or platinum oxide. 11. A process for preparing a compound of the formula
Figure imgf000083_0002
wherein R1 and R2 are as defined in claim 1 , which comprises treating a compound of the formula
Figure imgf000084_0001
wherein R and R2 are as defined in claim 1, with a methylating agent.
12. The process of claim 11 wherein the methylating agent is formaldehyde.
13. A process for preparing a compound of the formula
Figure imgf000084_0002
herein R1 and Ra are as denned in claim 1 , which comprises treating a compound of the formula
Figure imgf000085_0001
wherein R1 and R2 are as defined in claim 1, with a reducing agent.
14. The process of claim 13 wherein the reducing agent is NaBH4 or platinum oxide.
15. A process for preparing a compound of the formula
Figure imgf000085_0002
wherein R1 and R2 are as defined In claim 1, which comprises treating a compound of the formula
Figure imgf000086_0001
wherein R1 and R2 are as defined in claim 1 , with a methylating agent.
16. The process of claim 15 wherein the methylating agent is formaldehyde.
17. A compound of the formula
Figure imgf000086_0002
or a pharmaceutically acceptable salt thereof, wherein:
Y is H, C,-C,0 alkyl, Cz-C10 alkenyl, C2-C10 alkynyl, -(CH2)mC6-C10aryl, -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(0)R21, -OC(0)R21, - NRJ1C(0)R", -C(0)NR*1R", -NR,1R", hydroxy, C,-Cβ alkyl, C,-C6 alkoxy, Cβ-C10 aryl, and 5- 10 membered heteroaryl;
R1 is an alpha-branched C3-C8 alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C5-C, cycloalkylalkyi group wherein the alkyl group is an alpha-branched C Ca alkyl group; a C,-C„ cycloalkyi or C5-C8 cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more CrC4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C,-C4 alkyl groups or halo atoms; or R1 is phenyl which may be optionally substituted with at least one subβtituent selected from CrC4 alkyl, C C alkoxy and CrC4 alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano; or R1 may be with a formula (a) as shown below:
Figure imgf000087_0001
wherein X is O, S or -CH2-, , , c, and d are each independently an integer ranging from 0 to 2 and a + b + c + d < 5; or R1 is CH2R24, wherein R24 is H, C,-C8alkyl, C2-C8alkenyl, Cz-Cβalkynyl, alkoxyalkyl or alkylthioalkyl containing from 1 to 6 carbon atoms in each alkyl or alkoxy group wherein any of said alkyl, alkoxy, alkenyl or alkynyl groups may be substituted by one or more hydroxyl groups or by one or more halo atoms; or a C3-Cβcycloalkyl or C5-C„cycloalkenyl either or which may be optionally substituted by methyl or one or more CrC4alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated or fully or partially unsaturated and which may optionally be substituted by one or more d-C4alkyl groups or halo atoms; or a group of the formula SR23 wherein R23 is Cr C8alkyl, C2-C8alkenyl, C2-CBalkynyl, C3-C8cycloalkyl, C5-C8cycloalkenyl, phenyl or substituted phenyl wherein the substituent is C C4alkyl, CrC4alkoxy or halo, or a 3 to 6 membered oxygen or sulphur-containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more CrC4alkyl groups or halo atoms; R2 is H or OH;
R3 is H, OH, or OCH3;
Rλ is H, -C(0)Rβ, -C(0)OR9, -C(0)NR9 R10 or a hydroxy protecting group; Rs Is -SRB, -(CH2)„C(θ)R* wherein n Is o or 1, C,-C10 alkyl, C2-C10 alkenyl, C2-
C-ID alkynyl, -(CH2) (Cβ-Cl0 aryl), or -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R5 groups are optionally substituted by 1 to 3 R16 groups; each R' and R7 is independently H, hydroxy, CrCβ alkoxy, C,-Cβ alkyl, C2-Cβ alkenyl, C2-Ce alkynyl, -(CH2)m(Cβ-C10 aryl), or -(CH2)m(6-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4; each R8 is independently H, C,-C,0 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, -(CH2)qCR11Rl2(CH2)rNR1 Ru wherein q and r are each independently an integer ranging from o to 3 except q and r are not both o, -(CH2)m(Cβ-C10 aryl). or -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4. and wherein the foregoing Rβ groups, except H, are optionally substituted by 1 to 3 R1B groups; or where Rβ is as -CH2NRBR15, Rιa and Rβ may be taken together to form a 4-10 membered monocyclic or poiycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S and -N(R8)-, in addition to the nitrogen to which R1S and R8 are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R16 groups; each R9 and R10 is independently H or 0,-Cg alkyl; each R11, R12, R13 and R14 is independently selected from H, d-C™ alkyl, -(CHa)m(C„- C10 aryl), and -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R11, R12, R13 and R14 groups, except H, are optionally substituted by 1 to 3 R16 groups; or R11 and R13 are taken together to form -(CHZ)P- wherein p is an integer ranging from 0 to 3 such that a 4-7 membered saturated ring is formed that optionally includes 1 or 2 carbon-carbon double or triple bonds; or R13 and R14 are taken together to form a 4-10 membered monocyclic or poiycyclic saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S and -N(R8)-, in addition to the nitrogen to which R13 and R14 are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 R1β groups;
R15 is H, 0,-0,0 alkyl, C2-C10 alkenyl, or CrC,0 alkynyl, wherein the foregoing R15 groups are optionally substituted by 1 to 3 substituents independently selected from halo and - OR9; each R1β is independently selected from halo, cyano, nitro, trifluoromethyl, azido, -
C(0)R17, -C(0)OR17, -C(0)OR17, -OC(0)OR17, -NRβC(0)R7, -C(0)NR6R7, -NR6R7, hydroxy, C,-C6 alkyl, C,-C6 alkoxy, -(CH2)m(C6-Cl0 aryl), and -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein said aryl and heteroaryl subsituents are optionally substituted by 1 or 2 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(0)R17, -C(0)0R17, -C(0)0R17, -OC(0)OR17, -NR6C(0)R7, - C(0)NR6R7, -NR6R7, hydroxy, -Cβ alkyl, and C,-Cβ alkoxy; each R17 is independently selected from H, C-,-Cιa alkyl, CrC10 alkenyl, C2-C10 alkynyl, -(CH2)m(C8-C10 aryl), and -(CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, provided that Rβ is not H where R1B is -CH2S(0)„R8; R18 is OH;
R1β is CrC10 alkyl, CrC10 alkenyl. C2-C10 alkynyl, cyano, -CH2S(0)„R8 wherein n is an integer ranging from 0 to 2, -CH2ORβ,
Figure imgf000089_0001
-CH2NRBR15, -(CH2UC6-C10 aryl), or - (CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the foregoing R19 groups are optionally substituted by 1 to 3 R1β groups; or R1β and R19 are taken together to form an oxazolyl ring as shown below
Figure imgf000089_0002
and; each R21 and R22 is independently H, hydroxy, C,-C6 alkoxy, C-|-C8 alkyl, C2-Cβ alkenyl, (CH2)m(Cβ-C10) aryl, (CH2)m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, or C2-C10 alkylyl,
PCT/IB1998/002099 1998-01-02 1998-12-21 Novel macrolides Ceased WO1999035156A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
PL98341642A PL341642A1 (en) 1998-01-02 1998-12-21 Novel macrolydes
BR9814601-7A BR9814601A (en) 1998-01-02 1998-12-21 "macrolides"
HU0100420A HUP0100420A3 (en) 1998-01-02 1998-12-21 Novel macrolides and process for preparing them
US09/554,988 US6472371B1 (en) 1998-01-02 1998-12-21 Macrolides
HR20000442A HRP20000442A2 (en) 1998-01-02 1998-12-21 Novel macrolides
CA002316919A CA2316919C (en) 1998-01-02 1998-12-21 Novel macrolides
JP2000527552A JP2002500230A (en) 1998-01-02 1998-12-21 New macrolide antibiotics
AU14447/99A AU756409B2 (en) 1998-01-02 1998-12-21 Novel macrolides
KR1020007007313A KR100352809B1 (en) 1998-01-02 1998-12-21 Novel macrolides
IL13702498A IL137024A0 (en) 1998-01-02 1998-12-21 Novel macrolides
EP98958384A EP1044207A1 (en) 1998-01-02 1998-12-21 Novel macrolides
SK978-2000A SK9782000A3 (en) 1998-01-02 1998-12-21 Macrolides, method for production thereof and pharmaceutical compositions on their base
NZ504986A NZ504986A (en) 1998-01-02 1998-12-21 Erythromycin and azalide derivatives and pharmaceutical compositions thereof, useful as antibacterial agents and antoprotozoa agents
EA200000594A EA200000594A1 (en) 1998-01-02 1998-12-22 NEW MACROLIDES
IS5528A IS5528A (en) 1998-01-02 2000-06-09 New macrolide
NO20003347A NO20003347L (en) 1998-01-02 2000-06-27 New macrolides
BG104644A BG104644A (en) 1998-01-02 2000-07-28 Novel macrolides
US10/209,682 US7015203B2 (en) 1998-01-02 2002-07-30 Macrolides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7034398P 1998-01-02 1998-01-02
US60/070,343 1998-01-02

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09554988 A-371-Of-International 1998-12-21
US09/554,988 A-371-Of-International US6472371B1 (en) 1998-01-02 1998-12-21 Macrolides
US10/209,682 Division US7015203B2 (en) 1998-01-02 2002-07-30 Macrolides

Publications (2)

Publication Number Publication Date
WO1999035156A1 true WO1999035156A1 (en) 1999-07-15
WO1999035156B1 WO1999035156B1 (en) 1999-10-21

Family

ID=22094723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/002099 Ceased WO1999035156A1 (en) 1998-01-02 1998-12-21 Novel macrolides

Country Status (34)

Country Link
US (2) US6472371B1 (en)
EP (1) EP1044207A1 (en)
JP (1) JP2002500230A (en)
KR (1) KR100352809B1 (en)
CN (1) CN1284081A (en)
AP (1) AP9801420A0 (en)
AR (4) AR014948A1 (en)
AU (1) AU756409B2 (en)
BG (1) BG104644A (en)
BR (1) BR9814601A (en)
CA (1) CA2316919C (en)
CO (1) CO4970821A1 (en)
CZ (1) CZ20002458A3 (en)
DZ (1) DZ2698A1 (en)
EA (1) EA200000594A1 (en)
GT (1) GT199800206A (en)
HR (1) HRP20000442A2 (en)
HU (1) HUP0100420A3 (en)
IL (1) IL137024A0 (en)
IS (1) IS5528A (en)
MA (1) MA24729A1 (en)
NO (1) NO20003347L (en)
NZ (1) NZ504986A (en)
OA (1) OA11438A (en)
PA (1) PA8465301A1 (en)
PE (1) PE20000049A1 (en)
PL (1) PL341642A1 (en)
SK (1) SK9782000A3 (en)
TN (1) TNSN98238A1 (en)
TW (1) TW520374B (en)
UY (2) UY25330A1 (en)
WO (1) WO1999035156A1 (en)
YU (1) YU41500A (en)
ZA (1) ZA9811939B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0984019A1 (en) * 1998-08-19 2000-03-08 Pfizer Products Inc. C11 carbamates of macrolide antibacterials
US6399582B1 (en) 1999-04-16 2002-06-04 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
US6590083B1 (en) 1999-04-16 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
WO2003072589A1 (en) * 2002-02-26 2003-09-04 Meiji Seika Kaisha, Ltd. Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these
US6794366B2 (en) 1999-04-16 2004-09-21 Kosan Biosciences, Inc. Macrolide antiinfective agents
EP1437360A3 (en) * 1998-08-19 2005-04-06 Pfizer Products Inc. C11 Carbamates of macrolide antibacterials
US7015203B2 (en) 1998-01-02 2006-03-21 Pfizer Inc. Macrolides
EP1754700A2 (en) 1999-01-27 2007-02-21 Kosan Biosciences, Inc. Synthesis of oligoketides
CN103965273A (en) * 2013-08-23 2014-08-06 普莱柯生物工程股份有限公司 Macrolide compound

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
EA200100983A1 (en) 1999-05-24 2002-10-31 Пфайзер Продактс Инк. DERIVATIVES 13-METHYLERITROMYCIN
BRPI0515917A (en) 2004-09-23 2008-08-12 Schering Plough Ltd control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives
EP1811841B1 (en) * 2004-11-19 2009-10-28 Schering-Plough Ltd. Control of parasites in animals by the use of parasiticidal 2-phenyl-3-(1h-pyrrol-2-yl) acrylonitrile derivatives
UA85937C2 (en) 2004-12-21 2009-03-10 Пфайзер Продактс Інк. Macrolide compounds
WO2006135648A2 (en) * 2005-06-09 2006-12-21 Schering-Plough Ltd. Control of parasites in animals by n-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and n-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives
US8119667B2 (en) * 2005-12-29 2012-02-21 Schering-Plough Animal Health Corporation Carbonates of fenicol antibiotics
US20070238700A1 (en) * 2006-04-10 2007-10-11 Winzenberg Kevin N N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites
WO2008076259A1 (en) * 2006-12-13 2008-06-26 Schering-Plough Ltd. Water-soluble prodrugs of florfenicol and its analogs
CA2672795A1 (en) * 2006-12-13 2008-06-26 Schering-Plough Ltd. Water-soluble prodrugs of chloramphenicol, thiamphenicol, and analogs thereof
TWI430995B (en) 2007-06-26 2014-03-21 Du Pont Naphthalene isoxazoline invertebrate pest control agents
KR101769728B1 (en) 2007-06-27 2017-08-18 이 아이 듀폰 디 네모아 앤드 캄파니 Animal pest control method
WO2009064953A1 (en) * 2007-11-15 2009-05-22 Enanta Pharmaceuticals, Inc. Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
TWI468407B (en) 2008-02-06 2015-01-11 Du Pont Mesoionic pesticides
WO2010014566A2 (en) * 2008-07-30 2010-02-04 Intervet International B.V. Process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol
UA110924C2 (en) 2009-08-05 2016-03-10 Е. І. Дю Пон Де Немур Енд Компані Mesoionic pesticides
KR20120050467A (en) 2009-08-05 2012-05-18 이 아이 듀폰 디 네모아 앤드 캄파니 Mesoionic pesticides
US20120122680A1 (en) 2009-08-05 2012-05-17 E.I. Du Pont De Nemours And Company Mesoionic pesticides
UA107804C2 (en) 2009-08-05 2015-02-25 Du Pont MIXTURES OF MESOIONIC PESTICIDES
UA108881C2 (en) 2010-05-27 2015-06-25 CRYSTAL FORM 4- $ 5- $ 3-CHLORINE-5- (TRIFLUOROMETHYL) PHENYL] -4,5-DIHYDRO-5- (TRIFLUORMETHYL) -3-ISOXAZOLYL] -N- $ 2-OXO-2 - $ 2,2 -TRIFLUOROTHYL) AMINO] ETHYL] -1-NAPHTHALINE CARBOXAMIDE
WO2012087630A1 (en) 2010-12-20 2012-06-28 E.I. Du Pont De Nemours And Company Pyridine and pyrimidine compounds for controlling invertebrate
KR20140004187A (en) * 2011-01-31 2014-01-10 메이지 세이카 파루마 가부시키가이샤 Novel macrolide derivative
JP2014520151A (en) 2011-06-20 2014-08-21 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Heterocyclic compounds for treating helminth infections
CN102260306B (en) * 2011-07-22 2012-07-18 山东鲁抗舍里乐药业有限公司 Novel method for preparing tulathromycin
TW201326128A (en) 2011-11-28 2013-07-01 Du Pont Sulfonamide anthelmintics
WO2013158422A1 (en) 2012-04-17 2013-10-24 E. I. Du Pont De Nemours And Company Heterocyclic compounds for controlling invertebrate pests
WO2014099837A1 (en) 2012-12-18 2014-06-26 E. I. Du Pont De Nemours And Company Sulfonamide anthelmintics
CN105669798B (en) * 2013-08-23 2019-07-26 普莱柯生物工程股份有限公司 A kind of macrolides compound

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283055A2 (en) * 1987-09-03 1988-09-21 SOUR PLIVA farmaceutska, Kemijska prehrambena i kozmeticka industrija, n.sol.o. 10-Dihydro-10-deoxo-11-azaerythronolide-A-compounds, methods and intermediates for the manufacture thereof and their use in pharmaceuticals and in the manufacture thereof
FR2691464A1 (en) * 1992-05-21 1993-11-26 Roussel Uclaf New 1-oxa-6-aza-cyclopentadecane-13,15-di:one derivs. - useful as antibiotics for treating wide range of bacterial infections
EP0619320A1 (en) * 1991-12-27 1994-10-12 Taisho Pharmaceutical Co. Ltd 5-o-desosaminylerythronolide derivative
WO1998056802A1 (en) * 1997-06-11 1998-12-17 Pfizer Products Inc. 4'-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
WO1998056801A1 (en) * 1997-06-11 1998-12-17 Pfizer Products Inc. C-4''-substituted macrolide derivatives

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652537A (en) 1969-11-21 1972-03-28 Lilly Co Eli Epierythromycylamine and epierythromycyl b amine
US3923784A (en) 1973-09-10 1975-12-02 Hoffmann La Roche Erythromycin a derivatives
SI7910768A8 (en) 1979-04-02 1996-06-30 Pliva Pharm & Chem Works Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4585759A (en) 1985-01-22 1986-04-29 Pfizer Inc. Antibacterial derivatives of a neutral macrolide
US5141926A (en) 1990-04-18 1992-08-25 Abbott Laboratories Erythromycin derivatives
US5824513A (en) 1991-01-17 1998-10-20 Abbott Laboratories Recombinant DNA method for producing erythromycin analogs
WO1993013663A1 (en) 1992-01-17 1993-07-22 Abbott Laboratories Method of directing biosynthesis of specific polyketides
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
CA2065218A1 (en) 1991-04-11 1992-10-12 Robert R. Wilkening Process for the preparation of 9-deoxo-8a-aza-8a-homoerythromycin a and its 8a-alkyl derivatives
US5332807A (en) * 1993-04-14 1994-07-26 Merck & Co., Inc. Process of producing 8A- and 9A-azalide antibiotics
US5441939A (en) * 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
US6271255B1 (en) 1996-07-05 2001-08-07 Biotica Technology Limited Erythromycins and process for their preparation
WO1998051696A1 (en) 1997-05-09 1998-11-19 Pfizer Products Inc. Erythromycin derivatives
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
US20020025937A1 (en) 2000-03-20 2002-02-28 Yong-Jin Wu 9-oxime erythromycin derivatives
WO1999000124A1 (en) 1997-06-26 1999-01-07 Merck & Co., Inc. 9a-azalides, compositions containing such compounds and methods of treatment
US6339063B1 (en) 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
PA8461401A1 (en) 1997-10-29 2000-05-24 Pfizer Prod Inc TRICYCLIC ERYTHROMYCINE DERIVATIVES
HN1998000159A (en) 1997-10-29 1999-02-09 Monsanto Co DERIVATIVES OF 9- AMINO - 3 CETO ERITROMICINA
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
AP9801420A0 (en) 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
PT941998E (en) 1998-03-03 2004-12-31 Pfizer Prod Inc MACROLIDAN ANTIBIOTICS OF TYPE 3,6-CETAL
AU3439899A (en) 1998-06-03 1999-12-20 Pfizer Products Inc. Tricyclic 3-keto derivatives of 6-o-methylerythromycin
US6043227A (en) 1998-08-19 2000-03-28 Pfizer Inc. C11 carbamates of macrolide antibacterials
US6100240A (en) 1998-10-09 2000-08-08 Pfizer Inc Macrolide derivatives
KR20010083944A (en) 1998-11-03 2001-09-03 실버스타인 아써 에이. Novel macrolide antibiotics
UA70972C2 (en) 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-membered azalides and use thereof as antibiotics
EA200100983A1 (en) 1999-05-24 2002-10-31 Пфайзер Продактс Инк. DERIVATIVES 13-METHYLERITROMYCIN
EP1101769A3 (en) 1999-11-18 2001-10-24 Pfizer Products Inc. Nitrogen containing erythromycin derivatives
JP4311203B2 (en) 2001-08-08 2009-08-12 大正製薬株式会社 11a-azalide compound and method for producing the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283055A2 (en) * 1987-09-03 1988-09-21 SOUR PLIVA farmaceutska, Kemijska prehrambena i kozmeticka industrija, n.sol.o. 10-Dihydro-10-deoxo-11-azaerythronolide-A-compounds, methods and intermediates for the manufacture thereof and their use in pharmaceuticals and in the manufacture thereof
EP0619320A1 (en) * 1991-12-27 1994-10-12 Taisho Pharmaceutical Co. Ltd 5-o-desosaminylerythronolide derivative
FR2691464A1 (en) * 1992-05-21 1993-11-26 Roussel Uclaf New 1-oxa-6-aza-cyclopentadecane-13,15-di:one derivs. - useful as antibiotics for treating wide range of bacterial infections
WO1998056802A1 (en) * 1997-06-11 1998-12-17 Pfizer Products Inc. 4'-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
WO1998056801A1 (en) * 1997-06-11 1998-12-17 Pfizer Products Inc. C-4''-substituted macrolide derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DJOKIC, SLOBODAN ET AL: "Erythromycin series. Part 11. Ring expansion of erythromycin A oxime by the Beckmann rearrangement", J. CHEM. SOC., PERKIN TRANS. 1 (1986), (11), 1881-90, XP002913052 *
DJOKIC, SLOBODAN ET AL: "Erythromycin series. Part 13. Synthesis and structure elucidation of 10-dihydro-10-deoxo-11-methyl-11-azaerythromycin A", J. CHEM. RES., SYNOP. (1988), (5), 152-3, XP002913051 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7015203B2 (en) 1998-01-02 2006-03-21 Pfizer Inc. Macrolides
EP1437360A3 (en) * 1998-08-19 2005-04-06 Pfizer Products Inc. C11 Carbamates of macrolide antibacterials
EP0984019A1 (en) * 1998-08-19 2000-03-08 Pfizer Products Inc. C11 carbamates of macrolide antibacterials
EP1754700A2 (en) 1999-01-27 2007-02-21 Kosan Biosciences, Inc. Synthesis of oligoketides
US6590083B1 (en) 1999-04-16 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
US6794366B2 (en) 1999-04-16 2004-09-21 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6458771B1 (en) 1999-04-16 2002-10-01 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
US6399582B1 (en) 1999-04-16 2002-06-04 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
WO2003072589A1 (en) * 2002-02-26 2003-09-04 Meiji Seika Kaisha, Ltd. Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these
CN103965273A (en) * 2013-08-23 2014-08-06 普莱柯生物工程股份有限公司 Macrolide compound
WO2015024298A1 (en) * 2013-08-23 2015-02-26 普莱柯生物工程股份有限公司 Macrolide compound
CN103965273B (en) * 2013-08-23 2016-05-25 普莱柯生物工程股份有限公司 A macrolide compound
US9765105B2 (en) 2013-08-23 2017-09-19 Pulike Biological Engineering, Inc. Macrolide compound

Also Published As

Publication number Publication date
HUP0100420A3 (en) 2003-07-28
DZ2698A1 (en) 2003-03-29
PE20000049A1 (en) 2000-02-07
IL137024A0 (en) 2001-06-14
BG104644A (en) 2001-01-31
US20040092459A1 (en) 2004-05-13
SK9782000A3 (en) 2001-12-03
HRP20000442A2 (en) 2001-04-30
CN1284081A (en) 2001-02-14
GT199800206A (en) 2000-06-21
HUP0100420A2 (en) 2001-07-30
KR100352809B1 (en) 2002-11-01
PL341642A1 (en) 2001-04-23
OA11438A (en) 2004-04-30
AU756409B2 (en) 2003-01-09
YU41500A (en) 2003-02-28
AP9801420A0 (en) 1998-12-31
AR020851A2 (en) 2002-05-29
AR020551A2 (en) 2002-05-15
CO4970821A1 (en) 2000-11-07
CA2316919C (en) 2004-10-26
MA24729A1 (en) 1999-07-01
IS5528A (en) 2000-06-09
NZ504986A (en) 2003-03-28
KR20010024818A (en) 2001-03-26
NO20003347L (en) 2000-08-28
TNSN98238A1 (en) 2005-03-15
TW520374B (en) 2003-02-11
US7015203B2 (en) 2006-03-21
NO20003347D0 (en) 2000-06-27
CZ20002458A3 (en) 2001-10-17
AU1444799A (en) 1999-07-26
UY25330A1 (en) 2000-12-29
PA8465301A1 (en) 2000-09-29
ZA9811939B (en) 2000-06-30
US6472371B1 (en) 2002-10-29
CA2316919A1 (en) 1999-07-15
AR019787A2 (en) 2002-03-13
UY25574A1 (en) 1999-09-27
EA200000594A1 (en) 2001-04-23
EP1044207A1 (en) 2000-10-18
WO1999035156B1 (en) 1999-10-21
AR014948A1 (en) 2001-04-11
BR9814601A (en) 2000-10-17
JP2002500230A (en) 2002-01-08

Similar Documents

Publication Publication Date Title
US6472371B1 (en) Macrolides
CA2292359C (en) Novel azalides and methods of making same
AU759019B2 (en) Novel erythromycin derivatives
US6777543B2 (en) 13-methyl erythromycin derivatives
IL189430A (en) 13-membered azalides and their use as antibiotic agents
WO1998056800A1 (en) 9-oxime erythromycin derivatives
EP0984019B1 (en) C11 carbamates of macrolide antibacterials
MXPA00006604A (en) Novel macrolides
EP1437360A2 (en) C11 Carbamates of macrolide antibacterials
MXPA00001110A (en) Novel azalides and methods of making same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 137024

Country of ref document: IL

Ref document number: P-415/00

Country of ref document: YU

Ref document number: 98813253.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09554988

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 504986

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 9782000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 14447/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998958384

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2316919

Country of ref document: CA

Ref document number: 2316919

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020007007313

Country of ref document: KR

Ref document number: PV2000-2458

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: P20000442A

Country of ref document: HR

Ref document number: 200000594

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/006604

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1998958384

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007007313

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2000-2458

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1020007007313

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 14447/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998958384

Country of ref document: EP